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The RUNX1/AML1 gene is a key regulator of hematopoiesis and it is the most frequently 
mutated gene in human leukemia. Loss-of-function of RUNX1 predisposes cells to 
leukemia, and with the acquisition of cooperating genetic alterations, the cells become 
fully leukemogenic. Conditional deletion of Runx1 in adult mice results in an increase of 
hematopoietic stem/progenitor cells which may serve as the target cell pool for leukemia. 
However, in most cases, Runx1 knockout mice do not develop spontaneous leukemia due 
to the phenomenon called “stem cell exhaustion”. Bone marrow transplantation 
experiments showed that Runx1 knockout stem cell maintenance was compromised, 
resulting in progressively decreasing contribution of Runx1 knockout stem cells to blood 
cell production. The development of leukemia from Runx1 knockout stem cells harboring 
property of exhaustion may therefore require accumulation of additional genetic 
alterations that prevent exhaustion. I employed retroviral insertional mutagenesis on 
conditional Runx1 knockout mice to identify additional genetic alterations that cooperate 
with loss-of-function of Runx1 in leukemogenesis.  
Runx1 knockout mice infected with MoMuLV retrovirus showed shorter latency 
of leukemia onset than wild type littermates. Majority of the Runx1 knockout mice 
developed early onset leukemia with myeloid features while majority of the wild type 
mice developed T-cell leukemia or lymphoma with varying onset time. This indicates 
that Runx1 knockout status drives myeloid tropism despite T- lymphotropism of 
MoMuLV virus. 710 retroviral integration sites were obtained using inverse PCR 
techniques from 63 Runx1-/- mice and 52 WT mice. From Runx1 knockout series, 15 
known and 5 novel common integration sites were identified. The locus that was most 
 vi
frequently affected in Runx1 knockout mice was the Gfi1/ Evi5 locus and majority of the 
mice with integrations at this locus showed early onset leukemia with myeloid features.   
Gfi1 is a stem-cell factor and Evi5 is known to be a cell cycle regulator whose 
overexpression leads to a delay in mitotic entry. Quantitative real-time PCR results 
showed that Evi5 was preferentially overexpressed due to integrations at the Gfi1/Evi5 
locus, without much change in Gfi1 levels. Experiments were carried out on Runx1 
knockout and wild type bone marrow cells retrovirally overexpressing GFI1 or EVI5, to 
study rescue of exhaustion and synergy with Runx1 knockout status in maintaining stem 
cells. In vitro experiments such as long term culture of stem cells showed clear synergy 
between loss of function of Runx1 and overexpression of EVI5, but not GFI1. Results 
from in vivo bone marrow transplantation experiments also demonstrated similar synergy. 
EVI5 overexpression maintained increased number of Runx1 knockout stem cells by 
preventing their exhaustion in recipient mice. The mechanism of Runx1 knockout stem 
cell exhaustion and rescue by EVI5 seems to be niche dependant since Runx1 knockout 
cells expressed lower levels of critical niche interaction factor, CXCR4 and CD49b 
which may result in impaired interaction with the stem-cell niche. Defective homing and 
niche interacting ability of Runx1 knockout bone marrow cells was confirmed by homing 
assay. Overexpression of EVI5 in Runx1 knockout cells restored normal levels of CXCR4 
and CD49b; and at the same time upregulated critical stem cell and antiapoptotic genes 
such as Bmi1, p21 and Bcl-2, thereby maintaining an expanded pool of aberrant Runx1 
knockout stem cells in the niche which may act as targets of further oncogenic hits. 
Finally, EVI5 was also found to be overexpressed in 44% of human RUNX1 related 
leukemia patients, acute myeloid leukemia M2 subtype with t (8; 21).  
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Chapter 1 – Introduction 
 
1.1 Hematopoiesis 
The term hematopoiesis refers to the formation and development of the cells of the blood. 
Vertebrate hematopoiesis traditionally has been divided into an early or primitive phase 
and a late or definitive phase. Primitive hematopoiesis produces only a restricted range of 
blood cell types, including primitive nucleated erythrocytes and macrophages. Definitive 
hematopoiesis is multilineage hematopoiesis that gives rise to all lineages of blood cells 
that populate the organism. Primitive blood cells, which populate the early embryo, have 
properties that diverge from those of their definitive counterparts. Thus, two waves of 
hematopoiesis are required for various physiological activities that are differentially 
mediated by the embryo at various phases of development. 
 
1.1.1 Hematopoiesis during development 
 In the human embryo, primitive hematopoiesis resides at first in the yolk sac outside the 
embryo. Nucleated erythroid cells arise in the aggregates of blood cells in the yolk sac, 
called blood islands and circulate through the embryo supplying oxygen and nutrients to 
the developing tissues. Pluripotent hematopoietic stem cells arise from within the embryo 
in a region described as the aorta-gonad-meso-nephros (AGM) region between 25 and 35 
days post coitus (Godin et al., 1995; Huyhn et al., 1995; Medvinsky et al., 1993; Tavian 
et al., 1996). As the embryo develops, definitive hematopoiesis appears in the fetal liver 
at approximately 5 weeks of gestation (Migliaccio et al., 1986) and it remains the primary 
site of hematopoiesis until mid-gestation. Around the 20th week of gestation, 
 2
hematopoiesis is established in the bone marrow (BM). Progressively, hepatic 
hematopoiesis decreases and the BM becomes the main site for formation of the blood 
cells (Golfier et al., 1999; Golfier et al., 2000) (Figure1.1). After birth, BM is the only 
site of blood formation. However, maturation, activation, and some proliferation of 
lymphoid cells occur in secondary lymphoid organs (spleen, thymus, and lymph nodes). 
The liver and spleen may resume their hematopoietic function under pathologic 
conditions, called extramedullary hematopoiesis (Marshall and Thrasher, 2001).  
In mice, the process of hematopoiesis follows similar developmental steps with 
primitive hematopoiesis taking place in the yolk sac and definitive hematopoiesis in the 
fetal liver of the embryo and BM of adults. Primitive hematopoiesis starts at embryonic 
day 7.5 (E7.5) at blood islands in the yolk sac. Around embryonic day 8.5, definitive 
hematopoietic progenitor cells which are multipotent and capable of lymphoid and 
myeloid differentiation are found in the AGM region. Isolated AGM cultured in vitro 
demonstrated that this region is a source of hematopoietic stem cells (Dzierzak and 
Medvinsky, 1995; Yokomizo et al., 2001). These immature cells begin to circulate 
following the onset of cardiovascular function and migrate to the developing fetal liver by 
E10, which serves as the site for definitive hematopoiesis that starts around E12. The 
liver serves as the predominant site of hematopoiesis until just before birth when the 
spleen and BM compartments become seeded with circulating stem cells. From that point 
on, the BM serves as the primary site of hematopoiesis. 
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AGM, aorta-gonad-mesonephros; PAS, Para-aortic splanchnopleure    






1.1.2 Multilineage hematopoiesis 
Every functional specialized mature blood cell is derived from a rare population of cells 
in the BM known as the hematopoietic stem cells (HSC). These stem cells represent a 
self-renewing population of cells that have the potential to generate progenitor cells that 
differentiate and become committed to a particular blood cell lineage. A single stem cell 
is capable of completely restoring the hematopoietic process. Two properties define these 
cells. First, they can generate more HSC, through a process of self-renewal. Second, they 
have the potential to differentiate into various progenitor cells that eventually commit to 






continuous production of sufficient, but not excessive, numbers of hematopoietic cells of 
all lineages. The pluripotent HSC can undergo a decision to either self renew or 
differentiate into committed progenitor cells. Once the process of differentiation is 
triggered, HSC generate progenitor cells, namely common lymphoid progenitor (CLP) 
and common myeloid progenitor (CMP) (Ling and Dzierzak, 2002; Ogawa, 1993; Akashi 
et al., 2000; Orkin, 2000; Kondo et al., 2003). These cells are committed to a given cell 
lineage; nevertheless, they are highly proliferative and undergo several successive stages 
of differentiation till they terminally differentiate into mature non dividing progeny that 
make up specific blood cell types. The CMP gives rise to myeloid and erythroid lineage 
through granulocyte/macrophage progenitors (GMPs) and megakaryocyte/erythroid 
progenitors (MEPs). GMPs differentiate into granulocytes including neutrophils, 
eosinophils, basophils; and monocytes which further differentiate into macrophages. 
MEPs differentiate into megakaryocytes/platelets and erythrocytes (Figure1.2). The 
myeloid lineage is involved in various functions such as innate immunity, adaptive 
immunity and blood clotting.  
The CLP gives rise to the lymphoid lineage, namely T, B and NK cells which 
form the cornerstone of the adaptive immune system. Lymphocyte progenitors leave the 
BM and mature in lymphoid organs, including the thymus, lymph nodes, and spleen; 
these provide specialized microenvironments for the expression of factors that move 
lymphocytes along their distinctive pathways of differentiation. B-cell development to the 
stage of the mature B lymphocyte is completed within the BM. Further differentiation 
into plasma cells or memory B-cells does not occur until the mature (but naïve) B 




















HSC, hematopoietic stem cell; LT, long term; ST, short term; MPP, multipotent progenitor; CMP, common 
myeloid progenitor; CLP, common lymphoid progenitor; MEP, megakaryocyte erythrocyte progenitor; 
GMP, granulocyte monocyte progenitor.  
 
Figure 1.2: Hematopoiesis differentiation chart. Maturation patterns of myeloid and 
lymphoid cells into their respective lineage.  
(Modified http://daley.med.harvard.edu/ assets/Willy/Willy_Frames4.htm)  
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T lymphocyte occurs within the BM. The precursor T lymphocytes then go to the thymus 
to complete maturation. When mature T lymphocytes leave the thymus, they are mature, 
(but naïve) Tc (T cytotoxic lymphocytes) or Th (T helper lymphocytes). Further 
differentiation does not occur until the mature T-cells encounter antigen (presented to the 
T-cell in association with MHC proteins on 3 types of antigen presenting cells: 
macrophages, B-cells and dendritic cells) (Schwarz and Bhandoola, 2006). 
 
1.1.3 Hematopoietic stem cell niche 
HSC usually reside in a highly specialized microenvironment called the stem cell niche 
that produces essential factors to maintain a pool of HSC that provides the appropriate 
numbers of mature blood cells throughout life.  Most primitive HSC are thought to be in 
a quiescent state in these niches and regulation of HSC is largely dependant on their 
interaction with the niche. The niche serves as both a means of preserving and protecting 
stem cells from potentially depleting stimuli such as apoptotic and differentiation stimuli; 
and as a means of protecting the host from the potential adverse effects of excessive stem 
cell activity. However, stem cells must be periodically activated to produce progenitor 
cells that are committed to produce mature cell lineages. Thus, maintaining a balance of 
stem cell quiescence and activity is the hallmark of a functional niche. The niche 
therefore produces signals for the localization, expansion and constraint of stem cells 
(Moore and Lemischka, 2006; Wilson and Trumpp, 2006). 
  HSC have a defined spatial organization in the BM cavity, with the most-
primitive cells being located in stem cell niches  near the endosteum of the bone — the 
layer of connective tissue that lines the medullary cavity of a bone. The endosteum is 
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lined with osteoblasts (bone generating cells) which are thought to secrete or activate a 
variety of factors such as angiopoietin-1 and CXCL12 (chemokine ligand 12) that 
regulate the maintenance or numbers of HSC in the BM (Arai et al., 2004; Calvi et al., 
2003; Zhang et al., 2003). Especially, SNO cells (spindle shaped, N-cadherin+, osteoblast 
cells) fulfill the function of niche cells on the endosteum of BM (Zhang et al., 2003).   
The second niche for HSC is the sinusoidal niche located in the vascular network (the 
sinusoids) of the BM and spleen, with two thirds of the HSC localized at this niche (Kiel 
et al., 2005), especially attached to CXCL12 abundant reticular cells or CAR cells. 
CXCL12  is also known as SDF-1 (stromal cell derived factor) and its main receptor is 
CXCR4 which is found on HSC (Peled et al., 1999; Sugiyama et al., 2006). High 
amounts of SDF-1 is secreted by both the CAR cells in the sinusoidal niche and the 
osteoblast cells lining the endosteal niche to which most of the HSC are attached. Thus, 
interaction of SDF-1 with its receptor CXCR4 found on HSC is essential for the 
interaction of the HSC with its niche, both endosteal and sinusoidal (Kollet et al., 2006; 
Sugiyama et al., 2006). Interrupting this localization of stem cells to the niche impairs 
engraftment or retention of normal HSC in the BM, preventing these cells from self-
renewing and contributing to blood formation (Sugiyama et al., 2006). Collectively, all 
the genetic and functional data indicate that the SDF-1–CXCR4 pathway is crucial and 
probably most important for retention and maintenance of adult HSC. In addition to 
CXCR4, other cell-surface receptors expressed on HSC  and several cell-surface adhesion 
molecules, including selectins and integrins, are involved in stem cell homing, 
localization and retention in the niche (Lapidot and Petit, 2002; Lapidot et al., 2005).  For 
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example, β1-integrin-deficient HSC fail to migrate to the BM after transplantation 
(Potocnik et al., 2000). 
The stem cells behave in a dynamic manner and often leave the BM 
(mobilization), circulate in the blood and return to endosteal niche or sinusoidal niche 
(homing). The release of HSC from their niche is observed during homeostasis, when a 
small number of HSC are constantly released into the circulation (Wright et al., 2001). 
Although their precise physiological role remains unclear, they might provide a rapidly 
accessible source of HSC to repopulate areas of injured BM (Lapidot and Petit, 2002). 
Alternatively, circulating HSC might be a secondary consequence of permanent bone 
remodeling that causes constant destruction and formation of HSC niches, therefore 
requiring frequent re-localization of HSC which are on the lookout for empty niche. 
Transplanted HSC also have the capacity to home back to and lodge in stem cell niche in 
recipients. The stem cell pool is tightly controlled in the body and it is essential that the 
circulating stem cells or transplanted stem cells have their homing and niche interacting 
machinery intact so as to find a new niche and maintain their stem cell properties. Defects 
in this machinery could lead to loss of stem cells in the body as is seen in CXCR4 
conditional knockout mice (Sugiyama et al., 2006). 
 
1.1.4 Growth factors important for hematopoiesis 
Hematopoietic stem and progenitor cell commitment depends upon the acquisition of 
responsiveness to certain growth factors. A large number of cytokines that turn on and off 
transcriptional regulators of blood cell fate at the appropriate times have been identified. 
Based on their function, one can distinguish stem cell factors that promote maintenance 
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of HSC (such as SCF) (Nishikawa et al., 2001), multilineage colony stimulating factors 
(CSF) that act on several lineages (for example GM-CSF or IL-3) and lineage-specific 
factors (such as G-CSF for granulocytes, M-CSF for monocytes or EPO for erythrocytes) 
(Barreda et al., 2004; Richmond et al., 2005). The CSF act in a stepwise manner inducing 
proper maturation of blood cells. IL-3 (multi-CSF) acts early, possibly even at the level 
of the pluripotent stem cell, to induce formation of the myeloid progenitors. GM-CSF 
acts at a slightly later stage, and induces formation of granulocyte and monocyte 
progenitors. M-CSF and G-CSF act still later to promote the formation of monocytes and 
granulocytic cells, respectively. The other category of growth factors are the interleukins. 
Interleukins are present at extremely low concentrations and have biological activity at 
concentrations as low as 10-12 M. They are produced by various sources of blood and 
stromal cells and mediate various functions (Table 1.1).  
Hematopoiesis is a continuous process throughout adulthood and production of 
mature blood cells equals their loss. The process of hematopoiesis is tightly regulated; 
however, due to genetic alterations in stem/progenitor cells, the balance between 
proliferation and differentiation of stem/progenitor cells is affected leading to 
accumulation of white blood cells in the body which are usually dysfunctional. This leads 





   Major source Major effects 
IL-1 Macrophages 
Stimulation of T-cells and antigen-presenting cells. 
B-cell growth and antibody production. 
Promotes hematopoiesis (blood cell formation). 
IL-2 Activated T-cells Proliferation of activated T-cells. 
IL-3 T lymphocytes Growth of blood cell precursors. 
IL-4 T-cells and mast cells B-cell proliferation. IgE production. 
IL-5 T-cells and mast cells Eosinophil growth. 
IL-6 Activated T-cells Synergistic effects with IL-1 or TNFα. 
IL-7 Thymus and BM stromal cells Development of T-cell and B-cell precursors. 
IL-8 Macrophages Chemo attracts neutrophils. 
IL-9 Activated T-cells Promotes growth of T-cells and mast cells. 
IL-10 Activated T-cells, B-cells and monocytes Inhibits inflammatory and immune responses. 
IL-11 Stromal cells Synergistic effects on hematopoiesis. 
IL-12 Macrophages, B-cells Promotes TH1 cells while suppressing TH2 functions 
IL-13 TH2 cells Similar to IL-4 effects 
IL-15 Epithelial cells and monocytes Similar to IL-2 effects. 
IL-16 CD8 T-cells Chemoattracts CD4 T-cells. 
IL-17 Activated memory T-cells Promotes T-cell proliferation. 
IL-18 Macrophages Induces IFNγ production. 
 












Leukemia is characterised by an accumulation of abnormal or dysfunctional blood cells, 
leading to suppression of normal hematopoiesis, including production of normal red 
blood cells (RBC), white blood cells (WBC) and platelets. In parallel with the 
understanding of normal hematopoiesis has come a recognition that hematopoietic 
stem/progenitor cell dysregulation is involved in leukemogenesis. The progression to 
leukemia, especially acute leukemia, involves accumulation of at least two or more 
mutational events that lead to enhancement of stem cell proliferation or acquisition of 
stem cell behavior by a progenitor cell, coupled with maturation inhibition. Leukemia can 
be classified into distinct types according to the clinical manifestation (acute or chronic), 
and the property of leukemic cells, particularly, the lineage (myeloid or lymphoid) and 
the maturity. 
Chronic leukemia — It is distinguished by the excessive build up of relatively mature, 
but abnormal, blood cells. Early in the disease, the people with chronic leukemia may not 
have many symptoms, but chronic leukemia gets worse progressively. It causes 
symptoms as the number of leukemic cells in the blood rises. Typically taking months to 
years to progress, the cells are produced at a much higher rate than normal cells, resulting 
in many abnormal white blood cells in the blood over time.  
Acute leukemia — It is characterized by the rapid growth of immature blood cells. The 
blood cells are very abnormal and cannot carry out their normal functions. The number of 
abnormal cells increases rapidly and the crowding makes the BM unable to produce 
healthy blood cells. Immediate treatment is required in acute leukemias due to the rapid 
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progression and accumulation of the malignant cells, which then spill over into the 
bloodstream and spread to other organs of the body. If left untreated, the patient will die 
within months or even weeks. The types of leukemia are also grouped by the type of 
white blood cell that is affected. Leukemia can arise in lymphoid or myeloid cells.  
 
1.3 Acute Myeloid Leukemia 
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of hematopoietic 
progenitor/precursor cells and the most common hematological malignancy.  In normal 
hematopoiesis, the myeloid progenitor gradually matures into a mature myeloid cell. 
However, in AML, the myeloid progenitor accumulates genetic changes which maintain 
the cell in its immature state and prevent differentiation (Fialkow, 1976). Such mutations 
alone do not cause leukemia; however, when such a differentiation arrest is combined 
with other mutations which affect genes controlling proliferation, the result is the 
uncontrolled growth of an immature clone of cells, leading to the clinical entity of AML 
(Fialkow et al., 1991). Specific cytogenetic abnormalities can be found in many patients 
with AML and the types of chromosomal abnormalities often have prognostic 
significance. The chromosomal translocations encode abnormal fusion proteins, usually 
involving transcription factors whose altered properties may cause the differentiation 
arrest. The clinical signs and symptoms of AML result from the fact that, as the leukemic 
clone of cells grows, it tends to displace or interfere with the development of normal 
blood cells in the BM. This leads to anemia, and thrombocytopenia.  
Much of the diversity and heterogeneity of AML stems from the fact that 
leukemic transformation can occur at a number of different steps along the differentiation 
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pathway (Bonnet and Dick, 1997). Modern classification schemes for AML recognize 
that the characteristics and behavior of the leukemic cell (and the leukemia) may depend 
on the stage at which differentiation was halted. Based on the extent of differentiation, 
AML can be further classified into subtypes. The majority of the literature on leukemia is 
using the French-American-British (FAB) classification, which was mainly based on the 
morphology of the abnormal cells, although immunophenotyping is needed to confirm a 
few specific subtypes (Table 1.2). 
 
1.3.1 The genetic basis for development of AML 
A number of risk factors for AML have been documented including exposure to ionizing 
radiations, organic solvents such as benzene and chemotherapeutic agents. The molecular 
basis of this disease needs to be elucidated so as to develop effective targeted therapies to 
kill the leukemic clones specifically. Two major types of genetic events have been 
described that are crucial for leukemic transformation: (1) alterations in myeloid 
transcription factors governing hematopoietic differentiation and (2) activating mutations 
of signal transduction intermediates (Steelman et al., 2004; de Koning et al., 1998). These 
processes are highly interdependent, since the molecular events changing the 
transcriptional control in hematopoietic progenitor cells modify the composition of signal 
transduction molecules available for growth factor receptors, while the activating 
mutations in signal transduction molecules induce alterations in the activity and 




FAB Subtype Description Comments 
M0 Undifferentiated Myeloperoxidase negative; myeloid markers positive 
M1 Myeloblastic with maturation Some evidence of granulocytic differentiation  
M2 Myeloblastic with maturation 
Maturation at or beyond the promyelocytic 
stage of differentiation; can be divided into 
those with and without t(8;21) RUNX1-
ETO fusion protein 
M3 Promyelocytic APL; most cases have t(15;17) PML-RARα or another translocation involving RARα 
M4 Myelomonocytic  
M4Eo Myelomonocytic with BM eosinophilia 
Characterized by inversion of chromosome 
16 involving CBFβ/PEBP2β  
M5 Monocytic  
M6 Erythroleukemia  
M7 Megakaryoblastic GATA1 mutations in those associated with Down’s syndrome 
AML1, Acute Myeloid Leukemia 1/ RUNX1; APL, Acute promyelocytic leukemia; PML, Promyelocytic 
leukemia; RAR-α, Retinoic acid receptor α. 
 
Table 1.2: French-American-British (FAB) classification of AML (Bennett et al., 
1976). Modified from Tenen D.G, 2003. 
 
 
A number of studies have pointed to the dominant role of transcription factors 
usually involved in normal hematopoiesis, in the pathogenesis of AML. The evidence for 
this comes from two separate areas of studies. Chromosome studies have established that 
translocations/inversions of transcription factors are the most common cytogenetic 
defects in AML. Cloning of chromosome breakpoints has shown that genes involved in 
the chromosome abnormalities are hematopoietic transcription factors, the functional loss 
of which results in the disruption of myeloid differentiation. In a number of AML cases 
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that do not show chromosomal translocations, mutations have been found in the coding 
regions of hematopoietic transcription factors. Thus, it can be concluded that the most 
common genetic mechanism that is associated with AML is the deregulation of a 
transcription factor due to mutations or chromosomal translocations (Tenen D.G, 2003). 
 
1.4 Transcription factors 
A transcription factor is defined by its ability to bind DNA and modulate the expression 
of its target genes. It usually contains three regions: the DNA-binding domain, the 
multimerisation domain and the effector domain, which modulates activation or 
repression of transcription (Semenza G L, 1998). Transcription factors do not generally 
act alone. They interact with other proteins in the context of a protein complex. Their 
transactivation and DNA binding activities are cooperatively enhanced by these 
interactions. Transcription factors play a major role in the regulation of gene expression 
and the distinct combinations of transcription factors expressed in each cell of an 
organism need to be regulated spatially and temporally. The alteration of a transcription 
factor’s functions or expression patterns usually results in a severe phenotype as 
illustrated by transcription factor deficient mice, which are often embryonic lethal or 
harbor dramatic developmental defects. The action of a transcription factor can be altered 
by mutations either in the transcription factor sequence itself or in its cis-regulatory 
elements. 
Germ-line point mutations in transcription factors, while rare, are observed in 
approximately 10% of genetic disorders for which the responsible gene is known 
(Jimenez-Sanchez et al., 2001). The majority of these mutations affect embryonic 
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development, demonstrating the importance of these proteins in early development. 
Somatic mutations in transcription factors are also often observed in cancer, especially in 
leukemia. These mutations include both point mutations and various chromosomal 
abnormalities. As mentioned before, many of the translocations involved in leukemia 
target transcription factors. It was shown recently that 38% and 44% of the genes 
involved in chromosomal abnormalities, associated with hematopoietic and solid tumors 
respectively code for regulators of transcription (Mitelman et al., 2004). Transcription 
factor mutations can have 3 consequences. There can be a gene dosage effect resulting in 
haploinsufficiency of the transcription factor function, or the mutant can act as a 
dominant negative and interfere with the wild type transcription factor (Semenza G L, 
1998). Gain of function mutants can also be generated, especially if the mutation is in an 
inhibitory domain of the protein. 
 
1.4.1 Transcription factors in hematopoiesis and leukemia 
Important information about the role of transcription factors in hematopoiesis has been 
obtained from studies involving either targeted disruption or overexpression of these 
factors (Table 1.3). Hematopoietic transcription factors include factors such as 
RUNX1/AML1, SCL and GATA2 which are involved in formation of almost all lineages, 
and differentiation factors, such as GATA1, PU.1 and CCAAT/enhancer binding protein-
α (C/EBPα), which usually affects only a single or small number of related lineages. 
Disruption of RUNX1/AML1 or SCL during development affects formation of the entire 
blood cell lineage, because these transcription factors function during development of 
HSC.  
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The RUNX1/AML1 gene is a key regulator of hematopoiesis involved in definitive 
hematopoiesis during development and in differentiation of adult HSC. It is also the most 
frequently mutated gene in human leukemia. The role of RUNX1/AML1 gene in 
hematopoiesis and leukemia is the focus of this thesis and it will be discussed in detail in 
the next section.  
GATA1 was the first 'lineage-specific' transcription factor to be described, and its 
role in the development of erythroid and megakaryocytic lineages has been elucidated in 
a number of studies (Shivdasani and Orkin, 1996; Orkin, 2000). GATA1 participates in 
the differentiation of CMPs to megakaryocyte/erythroid progenitors (MEPs) and not 
GMPs. This role is supported by studies involving targeted disruption of regulatory 
elements that resulted in selective loss of erythroid development (Shivdasani et al., 1997). 
The relative expression levels of GATA1 is critical for normal differentiation and a study 
reported that every pediatric patient that was analysed — with acute megakaryoblastic 
leukemia associated with Down's syndrome — harbored mutations in GATA1, whereas 
other M7 AML samples did not (Wechsler et al., 2002) (Table 1.4). 
PU.1 and C/EBPα are the 2 genes important in myeloid lineage development. In 
normal myelopoiesis, PU.1 seems to have two well-defined functions. The first is to 
mediate an early role in the development of a multipotential myeloid precursor, by 
promoting HSC differentiation. The second is a later role in the development of 
monocytes/macrophages (DeKoter et al., 1998; Anderson et al., 1999) . In mice, Pu.1 is 





Site of expression Hematopoietic phenotype in knockout 
mice and conditional knockout mice 
RUNX1 Hematopoietic cells, nervous tissue, skeletal muscle, reproductive tissue 
Knockout: lack of all definitive 
hematopoiesis 
Conditional knockout: impaired 
megakaryocytic maturation, defective B-cell 




(‘hemangioblasts’, HSC, MPPs, 
erythrocytes and megakaryocytes, 
endothelial cells, brain tissue 
Knockout: complete absence of yolk sac 
hematopoiesis, lack of angiogenesis 
Conditional knockout: decreased 
erythrocytes and megakaryocytes, impaired 
ST-HSC, normal LT-HSC 
PU.1 
Hematopoietic cells (HSC, CMPs, 
CLPs, GMPs, monocytes, 
granulocytes and B-cells) 
Knockout: lack of mature myeloid and B-
cells 
Conditional knockout: block prior to CMP 
and CLP stages, increased granulopoiesis, 
defective HSC 
CEBPα 
Hematopoietic cells (HSC, CMPs, 
GMPs, granulocytes), liver, adipose 
tissue 
Knockout: lack of GMPs and granulocytes, 
impaired monocytes, increased immature 
myeloid cells 
Conditional knockout: same as knockout 
mice, plus increased HSC self-renewal 
IRF8/ ICSBP1 
Hematopoietic cells (B-cells, 
macrophages, dendritic cells and 
stimulated T-cells) 
Knockout: increased susceptibility to viral 
infections, increased granulocytic cells, 
CML-like disease 
GFI1 
Sensory epithelial cells in the inner 
ear, neuroendocrine cells of the lungs, 
neutrophils, B and T-cells, HSC 
Knockout: reduction in earliest lymphoid 
progenitors, complete block in late 
neutrophil maturation, defective HSC 
CEBPε Preferentially in myeloid and lymphoid cells 
Knockout: abnormal late neutrophil 
maturation, block in eosinophil 
development, defective macrophage 
function 
C/EBP, CCAAT/enhancer binding protein; CLP, common lymphoid progenitor; CML, chronic myeloid leukemia; 
CMP, common myeloid progenitor; GFI1, growth factor independent 1; GMP, granulocyte/monocyte progenitor; IRF8, 
interferon-regulatory factor 8; LT-HSC, long-term hematopoietic stem cell; MPP, multipotential progenitor; PU.1, 
transcription factor encoded by SPI1; RUNX1, Runt-related transcription factor 1; SCL, stem-cell leukemia factor; 
ST-HSC, short-term hematopoietic stem cell. 
Table 1.3: Transcription factors involved in normal hematopoiesis-                       
expression, and knockout phenotypes (Rosenbauer and Tenen, 2007).  
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Pu.1 also leads to delayed development of granulocytes and T-cells (Scott et al., 1994; 
McKercher et al., 1996). PU.1 regulates almost all myeloid genes, including the receptors 
for GM-CSF, M-CSF and G-CSF. PU.1 mutations have been detected in 7% of 126 AML 
patients (Mueller et al., 2002). In general, the mutations were found in either the most 
immature FAB subtype (M0), myelomonocytic or monocytic (M4 or M5), or 
erythroleukemia (M6) — consistent with the normal role of PU.1 in hematopoiesis 
(Table 1.4). 
In contrast to PU.1, C/EBPα has a more specific function in granulopoiesis and is 
required for development of granulocytes. Non-conditional targeted disruption of 
C/EBPα results in a selective early block in granulocyte maturation, without affecting 
other hematopoietic lineages, including monocytes (Zhang et al., 1997). Analysis of adult 
hematopoiesis in conditional C/EBPα knockout models shows a block at the CMP to 
GMP stage. Loss of C/EBPα affects expression of the G–CSF receptor, but not the 
receptors for GM–CSF or M–CSF (Iwama et al., 1998). Mutations in C/EBPα gene have 
been found with an approximate frequency of  7–9% in all AML patients (Preudhomme 







Factor Mutations and effects 
Frequency 
in AML FAB Subtype 
RUNX1–ETO 
t(8;21) 
RUNX1 DNA-binding domain fused to the 
transcriptional corepressor ETO; downregulates 






Inversion of breaks in chromosome 16; joins 





PML fused to RARα; blocks myeloid 





MLL fused with one of 30 distinct partner 
proteins; believed to dysregulate HOX genes 
 
4-7% 





Missense, nonsense or frameshift mutations 
(often biallelic); clustered within the Runt 
domain 
 
9% M0 (most) 
PU.1 
Mutations decrease heterodimer formation and 
DNA binding*; PU.1 activity downregulated by 
RUNX1–ETO, P ML–RARα and FLT3–ITD 
 
<7% M0, M4, M5, M6 
C/EBPα 
Amino-terminal dominant negative; 
carboxyterminal loss of DNA binding 
 
7-9% M1, M2 (most), M4  






M7 with Down’s 
syndrome 
 
*Japanese cohort only. AML, Acute Myeloid Leukemia; AMKL, acute megakaryoblastic leukemia; CBFβ, core-
binding factor-β; C/EBPα, CCAAT/enhancer binding protein-α; FAB, French–American–British; FLT3, FMS-
related tyrosine kinase 3; GATA1, GATA-binding protein 1; HOX, homeobox; ITD, internal tandem duplication; 
MLL, mixed lineage leukemia; MYH11, myosin heavy chain 11; PML, promyelocytic leukemia; PU.1, 
transcription factor encoded by SPI1; RARα, retinoic acid receptor-α; RUNX1, Runt-related transcription factor 1. 
 
Table 1.4: Hematopoietic transcription factors altered in AML                 
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1.5 Transcription factor RUNX1/AML1 
 
1.5.1 Runt domain transcription factors 
The RUNX genes belong to a small family of heterodimeric transcription factors that 
control critical cell fate decisions in a number of different cell lineages (Downing et al., 
2000; Speck et al., 1999). This family is composed of two subunits: a DNA-binding α 
subunit (RUNX genes) and a non DNA-binding β subunit. The Runt domain, specific to 
the RUNX family of proteins, was first identified in Drosophila, which has 4 genes (Runt, 
Lozenge, RunxA and RunxB) (Rennert et al., 2003) coding for the α subunit, and 2 genes 
(Brother and Big Brother) for the β subunit. In contrast, mammals have three genes 
coding for the α subunit, RUNX1, RUNX2, and RUNX3 and only one for the β subunit, 





















The human genes coding for α subunits have a number of alternative names 
(Table 1. 5). Since RUNX1 was first identified in chromosomal rearrangements observed 
in patients with leukemia, it was also called Acute Myeloid Leukemia 1 (AML 1) 
(Miyoshi et al., 1991). At the same time, RUNX2 gene was identified as the gene that 
codes for a protein that regulates the transcription of the mouse polyomavirus and thus 
was called Polyomavirus enhancer binding protein 2 (PEBP2α) (Satake et al., 1989). It 
was also called CBFα because it was identified from the core binding factor (CBF) 
complex that binds to the core site of murine leukemia viruses (Wang et al., 1993). The 
official nomenclature from the Human Gene Nomenclature Committee 
(http;//www.gene.ucl.ac.uk/nomenclature/) renamed the genes RUNX1-3 and these names 




RUNX1 AML1 CBFα2 PEBP2αΒ 
RUNX2 AML3 CBFα1 PEBP2αΑ 
RUNX3 AML2 CBFα3 PEBP2αC 
 
 





The three α subunits are required in different biological systems, but they share 
many common features. They recognize the same DNA-binding site in the promoter 
region of their target genes (Pu/TACCPuC) and all of them heterodimerize with the β 
subunit, through the Runt domain. Their protein sequences are highly conserved with 
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more than 90% identity in the Runt domain. Moreover, all RUNX proteins have PPxY 
motif, a domain for the binding of WW domain-containing proteins, such as Yes-
associated protein (YAP), within their transcription activation domain (TAD). 
Furthermore, they share a distinct five amino acid sequence, VWRPY, at the C-terminus. 
VWRPY motif was shown to bind to a transcriptional repressor called Transducin-like 
enhancer (TLE), the mammalian homolog of Groucho in Drosophila, which recruits 
histone deacetylases (HDAC) to repress transcription (Figure 1.5).  
The genomic loci of the three mammalian RUNX genes are structurally highly 
conserved, in addition to their protein homology. RUNX3, which is the smallest α subunit, 
has the fewest number of exons, which are all conserved in RUNX1 and RUNX2. The 
genes downstream of RUNX2 and RUNX3 are paralogues of CLIC6 and DSCR1, which 
are found downstream of the RUNX1 gene. Finally, all three α subunits use 2 distinct 
promoters, distal (P1) and proximal (P2) (Figure 1.4) (Levanon and Groner, 2004). 




Figure 1.4: RUNX genomic loci. Common exons are shown in similar colors. Exons in 
the RUNT domain are shown in green. 5’UTR are in yellow for the P1 promoter and in 
orange for the P2 promoter. 3’UTR are in blue. Neighboring genes are indicated. 
(Modified from Levanon & Groner, 2004). 
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Interestingly, the three proteins are rarely expressed in similar cells (Levanon et 
al., 2001), suggesting that they have distinct functions and their expression is spatially 
and temporally regulated. The strongest evidence for this came from knockout mouse 
studies which showed that the three genes are, indeed, involved in distinct systems. 
Runx1 is required for definitive hematopoiesis as shown by the Runx1 knockout mice, 
which lack fetal liver hematopoiesis and show hemorrhaging (Wang et al., 1996; Okuda 
et al., 1996); Runx2 is required for bone formation and the differentiation of osteoblasts 
as illustrated by the Runx2 knockout mice, which show a lack of ossification and die soon 
after birth because of severe respiratory defects due to absence of rib cage (Otto et al., 
1997; Komori et al., 1997); Runx3 is involved in the development of the nervous system 
(Inoue et al., 2002; Levanon et al., 2002), spine and thymocytes (Taniuchi et al., 2002; 
Woolf et al., 2003).  Runx3 knockout mice show hyperproliferation of the gastric mucosa 
(Li et al., 2002); and limb ataxia due to defective dorsal root ganglion neurons. 
Germ-line mutations in both RUNX1 and RUNX2 genes are also responsible for 
human disorders. RUNX1 is mutated in a familial platelet disorder (FPD-AML) and 
RUNX2 is mutated in cleidocranial dysplasia (Mundlos et al., 1997). Finally, all three 
RUNX genes play an important role in tumor development. The involvement of RUNX1 
in leukemia is well known and will be discussed later; RUNX2 overexpression 
predisposes cells to T-cell lymphomas (Vaillant et al., 2002); and both hemizygous 
deletions and hypermethylation of the RUNX3 promoter have been identified in human 




1.5.2 RUNX1: Gene and Protein 
The human RUNX1 gene is mapped to chromosome 21q22.12 and spans 260 kb of 
genomic sequence. It contains 8 exons. The Runt domain, which is the most important 
functional domain, contains 128 amino acids, spanning from the end of exon 3 to exon 5 
(Figure 1.4, green exons). The Runt domain is essential for the DNA-binding activity of 
the protein as well as the heterodimerization with PEBP2β/CBFβ (Ito, 2008). Although 
the β subunit itself does not bind to DNA, it enhances DNA-binding affinity of α subunit 
(Ogawa et al., 1993) and also protects the α subunit from ubiquitination and degradation 
(Huang et al., 2001). A second domain called the transactivation domain (TAD), which is 
rich in proline, serine and threonine, is found in many RUNX1 isoforms (Figure 1.5). 
The TAD is essential for transactivation activity of the protein. Isoforms without TAD 
cannot transactivate target genes; on the other hand, these isoforms have been shown to 
suppress transactivation by competing with the full length RUNX1 proteins for DNA 
binding (Tanaka et al., 1995). Both the Runt and the TAD domains are involved in 
protein interactions (Figure 1.5). The RUNX1 protein also contains two regions essential 
for its nuclear localisation; a nuclear localisation signal (NLS), which is present at the 
end of the Runt domain; and the nuclear matrix targeting signal (NMTS) in the C-
terminal part of the protein, which is responsible for the interaction of the protein with the 
























NLS, nuclear localization signal; TAD, transcription activation domain  
 
Figure 1.5: RUNX1 domains and interactions. A diagram of RUNX1 protein with 
main functional domains, interacting proteins and sites of phosphorylation and 





1.5.3. Regulation of RUNX1 expression 
RUNX1 is regulated at the transcription and translational levels, resulting in a very 
accurate spatial and temporal expression pattern. There are two promoters, proximal (P2) 
and distal (P1), found in all 3 RUNX genes. They are spaced approximately 160 kilobases 
apart in RUNX1 and give rise to mRNAs with different 5’UTR and proteins with different 
N-terminal ends. A large number of different transcripts with distinct expression patterns 
are generated by the combination of different N-terminal ends and many alternative 
splicing events (Corsetti and Calabi, 1997). Though studies are still ongoing to identify 
activators and repressors that bind to RUNX1 regulatory regions, a few binding sites have 
already been identified. Binding sites for the RUNX transcription factors themselves, 
conserved in human and mouse, are present at the beginning of the P1 5’UTR (Drisi et al., 
2002). This suggests that RUNX proteins can autoregulate themselves by feedback 
mechanism. Binding sites for other transcription factors such as PU.1 and c-Myb that 
Runt domain TAD 
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have been shown to interact with RUNX1 are also present in the RUNX1 promoter 
(Levanon et al., 1996).  
RUNX1 is also regulated at the translational and post-translational levels. The 
extracellular signal-regulated kinase (ERK), a member of the MAPK family, 
phosphorylates RUNX1 on two serine residues at the beginning of the TAD (Figure 1.5) 
(Tanaka et al., 1996). This phosphorylation enhances the transactivation ability of 
RUNX1, but does not seem to affect its DNA-binding affinity. Phosphorylation of 
RUNX1 is thought to disrupt the interaction between RUNX1 and the co-repressor of 
transcription, Sin3A, activating the transactivation ability of RUNX1. Phosphorylation is 
also important for the turnover of the protein as the interaction with Sin3A protects 
RUNX1 from degradation. Finally, phosphorylation of RUNX1 also plays a role in the 
subnuclear localisation of the protein to the nuclear matrix (Imai et al., 2004). p300 has 
been shown to acetylate two Lysine residues (24 and 43), present N-terminal to the Runt 
domain (Figure 1.5), which leads to increased DNA binding affinity of RUNX1. 
Acetylation of these two residues also increases the transactivation activity of RUNX1, 
but does not affect heterodimerization with CBFβ/PEBP2β (Yamaguchi et al., 2004). 
Finally, a negative regulatory region that regulates DNA-binding activity and also 
dimerization with CBFβ/PEBP2β is found in the long RUNX1 isoforms. The 
conformation of these regions can change by interaction with other transcription factors, 
thus allowing interactions with DNA. For example, the interaction between ETS-1 and 
RUNX1 leads to reciprocal stimulation of their DNA affinity and activation of their 
transactivation function by changing their 3D structure, leaving the DNA-binding domain 
unprotected and free for binding (Kim et al., 1999). 
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1.5.4. Transcriptional activity of RUNX1 
RUNX1 recruits protein complexes to the promoters and enhancers of its target genes and 
thus acts as an organizing factor. RUNX1 function is context dependent based on the 
level of expression of cell-specific RUNX1 isoforms, the availability of co-factors and 
the signals triggering posttranslational modifications. Its function is also promoter-
specific as RUNX1 depends on other binding sites present in the regulatory regions of its 
target genes. Through these combinational mechanisms, RUNX1 can act as an activator 
of transcription as well as a repressor. 
 
1.5.4.1 Activation of transcription 
RUNX1, by itself, has only a small effect on the transcriptional level of its target genes. 
RUNX1 works in synergy with other transcription factors and co-activators to enable 
efficient activation of the transcription of its target genes (Mao et al., 1999; Petrovick et 
al., 1998).The majority of proteins that have been shown to interact with RUNX1 are 
involved in the hematopoietic system. Some of them are the hematopoietic lineage-
specific factors, illustrating the cell-specific action of RUNX1. For example, C/EBPα is 
expressed in myeloid cells, while ETS-1 is expressed only in lymphoid cells, and PU.1 in 
both lineages. The well-known co-activators of RUNX1 are CREB (cAMP response 
element binding protein) and core binding protein (CBP)/p300, which has histone 
acetyltransferase (HAT) activity. CBP/p300 is important for active chromatin remodeling 
by histone acetylation and acts as protein bridges between the sequence-specific 
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transcription factors, such as RUNX1, and the basic transcriptional machinery on the 
promoter of the target gene, thereby enhancing its transcription.  
 
1.5.4.2. Repression of transcription 
RUNX1 protein can also act as a transcriptional repressor (Durst and Hiebert, 2004). The 
mechanisms of repression, which are cell and promoter specific, are direct repression and 
gene silencing. Direct repression is a reversible mechanism, whilst gene silencing is a 
long term mechanism as it is maintained during cell division. In the case of CD4 gene 
silencing, for example, both mechanisms are used at two different developmental stages. 
RUNX1 is required for an active repression of CD4 in double negative thymocytes, 
whilst RUNX3 and probably RUNX1 are required for the establishment of epigenetic 




Figure 1.6: CD4 repression / silencing 
Runx1 binds the CD4 silencer and is required to repress transcription in immature 
double-negative (DN) thymocytes. Runx3 establishes CD4 epigenetic silencing in CD4-






In order to repress transcription, RUNX1 transcriptional complexes can recruit repressors 
such as TLE/Groucho at the C-terminal end of the protein via the VWRPY motif 
(Levanon et al., 1998) and Sin3A downstream of the Runt domain (Figure 1.5). Rather 
than directly binding DNA, TLE/Groucho and Sin3A interact with transcription factors 
and recruit histone deacetylases in order to repress transcription. Knock-in mouse studies 
have demonstrated that the motif VWRPY is not essential for the development of 
hematopoietic cells (Nishimura et al., 2004) but is necessary for other functions such as 
thymocyte development. This illustrates again the cell-specific activity of RUNX1.  
Gene silencing 
RUNX1 can also directly interact with HDAC proteins, which promote gene silencing. 
RUNX1 has been shown to interact strongly with HDAC1, 3 and 9 but only weakly with 
HDAC2, 5 and 6 in vitro. RUNX1 is also involved in gene silencing through the 
recruitment of SUV39H1 (Durst & Hiebert, 2004) (Table 1.6). 
 
1.5.5 Target genes of RUNX1 
A number of genes have already been described as target genes of RUNX1. The majority 
of these studies have focused on specific genes known to be involved in the 
hematopoietic system. However, they are mainly based on in vitro studies, and whether 
their expression is really transcriptionally regulated by RUNX1 in vivo remains elusive. 
Table 1.7 lists some of target genes of RUNX1 reported to date. They include growth 
factors, receptors, and cell surface molecules, signaling molecules, transcription 
activators and others.  
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Interacting proteins  Description  Clinical leukemia association 
Activation   
ETS1  TF; ETS family  
ELF4 (MEF) TF; ETS family  
SPI1 (PU.1) TF; ETS family Point mutation in 7% of AML  
ELF2 (NERF2) TF; ETS family  
CEBPA TF Point mutation in AML 
Pax5 TF; paired box gene t(9;12) Pax5-ETV6/TEL (ALL)
MITF TF; bHLH-Zip family  
ZNFN1A1 (Ikaros) TF; zinc finger t(3;7) Bcl6-Ikaros; high-level expression in ALL infants 
JUN (AP1) TF  
GATA1 TF Point mutations in DS - AMKL
ATF2 (CREBP1) Cyclic AMP   
LEF1 Architectural protein  
THOC4 (ALY) Protein interaction  
CREBBP (CBP) Transcriptional adaptor; HAT t(8;16) CBP-MOZ 
SMAD3  Signaling molecule  
MYST3 (MOZ) Histone acetyl transferase t(8;16) CBP-MOZ 
Repression   
TLE1,2 (Groucho) Protein interaction  
Sin3A Histone deacetylase  
NR2F6 (Ear2) Nuclear hormone receptor family  
ELF2 (NERF 1a) TF; ETS family  
HDAC1,3,9 Histone deacetylases  
SUV39H1 Histone methyltransferase  
DS, Down’s syndrome; AMKL, Acute megakaryocytic leukemia; HAT, Histone acetyl transferase; TF, 
Transcription factor 
 
Table1.6: RUNX1 interacting proteins. The association of the interacting proteins with 
leukemia development is indicated. 
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Gene Description Affected cell type 
Growth factors   
GM-CSF Granulocyte-macrophage colony stimulating factor 
granulocytes, macrophages, 
eosinophils  & progenitors 
IL-3 Interleukin-3 mature/immature myeloid / lymphoid 
Receptors   
M-CSFR Macrophage colony stimulating factor receptor  
macrophages, monocytes / 
progenitors 
TCR α, β, γ, δ  T-cell receptors α, β, γ, δ chain T-cell 
Surface molecules   
CD11a CD11a integrin T-cells, macrophages, neutrophils 
CD36  CD36 antigen; cell surface glycoprotein macrophages, monocytes 
Signal molecules   
BLK  B-lymphocyte specific tyrosine kinase B-cells 
p21CIP1 Cyclin dependent kinase inhibitor 1A myeloid / lymphoid 
Bcl-2 B- cell CLL/Lymphoma 2; prevent 
apoptosis 
myeloid / lymphoid 
p14ARF  Cyclin dependent kinase inhibitor 2A  myeloid / lymphoid 
CCND3  Cyclin D3  myeloid / lymphoid 
Transcription activators   
Fos Osteosarcoma viral oncogene homologue; AP-1 component  
Others   
MPO Myeloperoxidase Myeloid 
MMCP6  Mast cell protease 6  mast cells 
ELA2 Neutrophil elastase Myeloid 
GZMB  Granzyme B NK cells, cytotoxic T-cells 
 
 
Table 1.7: Targets of Runx1 regulation (modified from Peterson and Zhang, 2004).  
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 1.5.6 Role of Runx1 in hematopoiesis 
Runx1 knockout mice have largely illustrated the role of Runx1 in hematopoiesis. In wild 
type mice, Runx1 expression is seen as early as E8.5 at all sites from which definitive 
hematopoietic cells emerge later such as the yolk sac, the umbilical arteries and the AGM 
region (North et al., 1999). In Runx1 knockout embryos, there is a complete absence of 
definitive fetal liver hematopoiesis though primitive hematopoiesis is not impaired 
(Figure 1.7). Runx1 knockout embryos are unable to generate definitive hematopoietic 
cells from the endothelial cells in the AGM region (Yokomizo et al., 2001) and they die 
at E12.5 (Okuda et al., 1996; Wang et al., 1996). Hemorrhaging is also seen in the Runx1 
knockout embryos. The areas where hemorrhages occur are very specific and correspond 
to areas of high expression of Runx1. Cellular necrosis precedes hemorrhaging, 
suggesting a developmental defect in the endothelial cells of the central nervous system 














Figure 1.7: Runx1 knockout embryos lack definitive hematopoiesis 
Runx1 knockout mice die at E12.5 due to absence of fetal lever hematopoiesis (arrow). 




 Conditional knockout mice have recently demonstrated the role of Runx1 in adult 
mouse hematopoiesis (Growney et al., 2005; Ichikawa et al., 2004; Putz et al., 2006; 
Taniuchi et al., 2002; Motoda et al., 2007). Runx1-excised adult mice have an expanded, 
immunophenotypically defined HSC compartment. These mice survive for more than a 
year, indicating that there is long-term HSC activity in these animals. This finding is 
surprising in light of the hematopoietic defect observed in Runx1 knockout embryos, 
which leads to the conclusion that Runx1 may be dispensable for maintenance of HSC in 
adult hematopoiesis. On the other hand, Runx1 is required for efficient lymphoid 
maturation at multiple stages of differentiation. There is a significant reduction in the 
number of mature peripheral blood (PB) B-cells and BM derived B-cell precursors in 
primary Runx1-excised mice which suggests a significant block in B-cell maturation. In 
the T-cell lineage, there is a specific block in T-cell maturation during the transition from 
the DN2 (CD44+CD25+) to the DN3 (CD44-CD25+) stage.  In contrast to the 
pronounced inhibition of the lymphoid lineage, excision of Runx1 does not inhibit 
maturation of the myeloid lineage.  Runx1-excised mice demonstrate expansion of the 
myeloid lineage by several phenotypic and functional criteria, with no evidence of a 
block in myeloid development. Runx1 loss has no apparent effect on the erythroid lineage, 
but it does have a significant effect on megakaryocytic maturation. Runx1 is required for 
normal maturation of the megakaryocyte lineage but not for the establishment of this 
lineage, leading to an accumulation of megakaryoblasts in Runx1-excised mice. Thus, 
Runx1 deficient mice have a higher number of stem/progenitor cell fractions, show 
abnormal differentiation of megakaryocytes leading to accumulation of megakaryoblasts 
and thrombocytopenia, and accumulation of immature lymphocytes cells due to defective 
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T- and B-cell development (Figure 1.8). However, the lack of Runx1 in adult mice does 












Figure 1.8: Adult hematopoiesis and affected lineages due to Runx1 deficiency  




Ichikawa et al. did not report the development of leukemia or other disease phenotypes in 
their conditional Runx1 knockout model. Another conditional knockout mouse model 
developed by Taniuchi et al also did not show any spontaneous leukemia phenotypes. 
Growney et. al. showed a mild myeloproliferative phenotype in Runx1 excised mice, with 
mild expansion of myeloid cells in the BM and spleen. Nevertheless, there was no 
leukemia development in these mice. Putz et al. also showed the moderate 
myeloproliferation with splenomegaly in their Runx1 conditional knockout model and 
some of the mice progressed to develop lymphoma at late stages of adulthood.  
 
Affected in RUNX leukemia 
Affected in conditional Runx1 knockout mouse 
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1.5.7 RUNX leukemia 
The RUNX1 gene is the most frequently mutated gene in human leukemias and genetic 
alterations of this gene are found in approximately 30% of all human AML. The genetic 
alterations of the RUNX1 gene could be either because of chromosomal translocations 
resulting in fusion protein products with RUNX1 or mutations in the RUNX1 gene itself.  
 
1.5.7.1 Chromosomal Translocations 
The PEBP2/CBF complex is one of the most frequent targets of chromosomal 
translocations associated with human leukemia and account for 20–25% of adult AML. 
RUNX1 is involved in many translocations and its co-factor PEBP2β/CBFβ is altered in 
an inversion of chromosome 16 associated with the AML M4Eo subtype (Liu et al., 
1993) (Figure 1.9). One of the most frequent translocations of the RUNX1 gene is the 
t(8;21) that fuses RUNX1 to the Eight twenty-one (ETO) gene (Licht, 2001). This 
translocation is found in 40% of patients with the AML M2 leukemia subtype.  All 
molecularly defined RUNX1-translocations are found in leukemias of the myeloid lineage 
except for the TEL-RUNX1 translocation, which is only found in the lymphoid lineage 
(Loh et al., 1998) (Table 1.8).  
After translocation, a normal copy of the gene is still present in the affected cells 
since the translocation usually affects only one copy of the translocated gene. The fusion 
proteins resulting from the translocations can contribute to leukemia pathogenesis by a 
variety of mechanisms including: 
- A dominant-negative effect of the fusion proteins on RUNX1 and/or its fusion partner 
- A gain-of-function due to the fusion itself 
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- Haploinsufficiency of wild type RUNX1 and/or its fusion partner 
- A combination of these mechanisms 
Nevertheless, studies in mice suggested that the translocations are not sufficient for the 




PNT, pointed domain; TA, transactivation domain; ZF, zinc finger  
Figure 1.9: CBF fusion genes that are associated with leukemia                          







1.5.7.2   Somatic point mutations 
Point mutations in the RUNX1 gene have been identified in various sporadic myeloid 
malignancies including various AML subtypes, atypical CML and MDS (Osato et al., 
2001; Osato et al., 1999). Majority of the mutations fall on the Runt domain and none of 
the typical leukemia-associated translocations are present in these leukemias. Monoallelic 
mutations in RUNX1 may predispose myeloid hematopoietic stem/progenitor cells to the 
development of a hematological malignancy, but the affected lineage and consequent 
type of malignancy depends upon which genes subsequently sustain additional somatic 
mutations. Indeed the phenotypes of leukemic cells with monoallelic mutations are varied, 
suggesting the occurrence of additional genetic events in a number of different molecules. 
Biallelic RUNX1 point mutations have also been observed and are tightly linked to the 
AML M0 subtype (Table 1.8) (Osato et al., 1999; Preudhomme et al., 2000). The AML 
M0 subtype is AML with minimal differentiation and shows accumulation of immature 
myeloid cells or blasts. AML M0 very frequently carries cytogenetic abnormalities such 
as -5/5q- or -7/7q- deletions and or complex karyotype and shows poor prognosis. 
RUNX1 proteins derived from point mutants are proved to be non-functional as a result of 
which biallelic mutations may result in blocked differentiation and continuous growth of 
stem/progenitor cells at the earliest stage of myeloid differentiation, thus contributing to 
accumulation of immature cells.   
 
 
1.5.7.3 Familial leukemia 
Germ-line monoallelic RUNX1 mutations have been identified in pedigrees with an 
autosomal dominant familial platelet disorder (FPD/AML; Song et al., 1999). Individuals 
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with the disease develop thrombocytopenia and show a propensity to develop AML. 
Because one pedigree harbors a complete deletion of one of the RUNX1 alleles, it has 
been suggested that haploinsufficiency of RUNX1 is responsible for this disease (Song et 
al., 1999). Our laboratory has established the mouse model for FPD/AML using the 
BXH2 mouse strain, which carries an ecotropic retrovirus that infects neonates through 
the milk. BXH2-Runx1+/- mice show shorter latency of leukemia onset, suggesting that 




Type FAB Subtype Phenotype Associated genetic defects 
AML M0 Undifferentiated Biallelic RUNX1 mutations 
 M1 Myeloblastic with maturation  
 M2 Myeloblastic with maturation t(8;21) RUNX1-ETO 
 M3 Promyelocytic t(15;17) PML-RARα 
 M4 Myelomonocytic  
 M4Eo Myelomonocytic with BM eosinophilia inv(16) CBFβ-MYH11 
 M5 Monocytic  
 M6 Erythroleukemia  
 M7 Megakaryoblastic GATA1 mutation in DS patients 
ALL B Lymphocytic B-cell leukemia t(21;12) TEL-RUNX1 
 T Lymphocytic T-cell leukemia  
CML  Myelocytic t(9;22) BCR-ABL 
CLL  Lymphocytic  
MDS    
 
Table 1.8: Description of selected leukemia subtypes and associated genetic defect. 
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1.5.7.4 Increased RUNX1 gene dosage 
Down syndrome (DS) patients with a constitutional trisomy 21, have a 10-20 fold 
increased risk of developing leukemia compared to the non-DS population. DS children 
account for approximately 2% and 13% of children diagnosed with ALL and AML 
respectively. The most frequent AML subtype observed in these children is the AML M7 
subtype (megakaryocytic). The etiological role of trisomy 21 in leukemogenesis could be 
due to increased proliferation of leukemic progenitor cells due to overexpression of a 
tumorigenic protein coded by one human chromosome 21 gene, such as RUNX1 (Osato 
and Ito, 2005). Furthermore, transgenic mice overexpressing Runx1 under the control of 
the GATA-1 promoter developed megakaryocytic leukemia as observed in DS patients 
(Yanagida et al., 2005), suggesting indeed that increased RUNX1 gene dosage might be 
responsible for the leukemia predisposition observed in DS patients. Interestingly, 
trisomy 21 is also among the most commonly observed acquired chromosomal 
abnormalities in leukemic BM, particularly in ALL (Berger, 1997). Extra copies of 
RUNX1 (2-8 copies) due to tandem repetition of chromosome 21 or the presence of a 
non-constitutional chromosome 21 were also observed in several patients with acute 
lymphoblastic leukemia (ALL) (Ferro et al., 2004; Mikhail et al., 2002). Together, an 
increase of RUNX1 dosage may also contribute to leukemogenesis. 
 
1.5.7.5 Multistep development of RUNX leukemias 
Various genetic alterations mentioned above such as translocations and point mutations 
in the RUNX1 gene lead to loss-of-function of RUNX1 which results in hematopoietic 
abnormalities to some extent. However, a series of mouse models designed to recapitulate 
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genetic alterations in human leukemias such as RUNX1-ETO conditional knock-in mice 
or majority of the Runx1 conditional knock-out mice models failed to develop 
spontaneous leukemia (Growney et al., 2005; Ichikawa et al., 2004; Higuchi et al., 2002). 
Moreover, chimeric genes involving RUNX1 are detected even in healthy volunteers 
(Basecke et al., 2002; Mori et al., 2002). Studies of children with t(12;21) translocation, 
having a chimeric gene TEL-RUNX1, showed that the translocation sometimes occurs in 
utero and that leukemia develops only after up to 9 years of latency (Ford et al., 1998).  
 Such ample evidence points to the model of multi-step leukemogenesis in which 
RUNX1 alteration per se does not readily result in leukemia but additional genetic 
changes, or “second hit”, are required for full-blown leukemia (Figure 1.10). The 
affected lineage and consequent type of leukemia, following a RUNX1 mutation, may 
depend upon which genes are somatically mutated as secondary hits (Michaud et al., 
2003). To identify the additional genetic alterations that cooperate with RUNX1 



















1.6 Retroviral insertional mutagenesis (RIM) 
 
RIM is a powerful tool to identify oncogenes and tumor suppressors that are important 
for carcinogenesis. In our laboratory, RIM has been used to study the effect of Runx1 




         
Figure 1.10: Secondary hit is required for full blown RUNX leukemia.  
Mutations in RUNX1 gene only predispose for the development of leukemia and 
secondary mutations are necessary for development of full blown leukemia (Reproduced 




1.6.1. Mechanism of RIM 
Oncogenic retroviruses are generally divided into two categories.  
(1) The acute transforming retroviruses induce polyclonal tumors within 2-3 weeks after 
infection. Their viral genes are replaced with transduced cellular gene, or a part of a gene, 
that is responsible for the oncogenic activity.  
(2) The slow-transforming retroviruses cause mono- or oligoclonal tumors after a latency 
period of several months. They do not carry viral oncogenes and their capacity to induce 
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neoplasms is based on the ability of their provirus to integrate in the host DNA, and 
mutate or transcriptionally activate flanking cellular genes. Insertions can occur over a 
broad distance (approximately 300 kb) upstream or downstream of many targeted loci, 
and the provirus can be in the same transcriptional orientation as the gene or in the 
opposite orientation (Jonkers and Berns, 1996). In this case, there are basically three 
mechanisms by which expression of host genes is affected by retroviral integration 
(Figure 1.11).  
(a) Activation by promoter insertion: 
 When a provirus integrates upstream of a proto-oncogene in the same transcriptional 
orientation, the promoter and enhancer elements in the proviral long terminal repeats 
(LTRs) can direct increased levels of proto-oncogene expression. In this case, one of the 
LTRs is fused with the targeted proto-oncogene. 
(b) Transcriptional enhancement: 
 Many proviruses are inserted upstream of target genes or downstream from target genes 
in either orientation. These proviruses seem to increase gene expression by placing the 
gene under the influence of strong enhancer elements within the retroviral U3 region. 
Occasionally, the proviruses are separated from the gene by as much as 300 kb. 
Transcriptional enhancement is probably the most frequent mechanism of gene activation 
by insertional mutagenesis, although the precise mechanism remains unclear. 
(c) Protein truncation by transcription termination: 
The integration of a provirus into the transcription unit can have adverse effects on the 
protein product. If viral insertion disrupts coding domains, the protein sequence can be 
completely mutated in such a way that an aberrant gene product with abnormal biologic 
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activity is produced. There are a few cases whereby viral integration inside a gene also 
results in activation of gene due to production of a constitutively active truncated protein 
such as activating integrations in the Notch gene (Feldman et al., 2000). 
 
1.6.2. The identification of oncogenes or tumor suppressors by RIM 
Somatic and clonal integration of retroviruses in the host genome may enhance proto-
oncogene expression or inactivate tumor suppressor genes. A cell that has such 
integrations acquires growth advantage, and is then clonally selected to become 
tumorigenic. In these cases, the oncogenes/tumor suppressors responsible for 
tumorigenesis can be identified by using proviral DNA as ‘a molecular tag’. High 
throughput cloning of retroviral integration sites (RIS) has been accomplished by 
employing the inverse polymerase chain reaction (IPCR) technique, and database 
mapping of RIS by using the mouse genome database (Yanagida et al., 2005; Suzuki et 
al., 2002). These studies have enabled the identification of multiple retroviral insertion 
sites in each tumor, and it could clarify cooperative genetic interactions in tumorigenesis, 
as retrovirally induced leukemias/lymphomas usually contain multiple integrations of 
proviral genomes within a single tumor clone. Practically, retroviral insertions have been 
achieved either in mouse strains with high endogenous retrovirus expression, such as 
BXH2 strain, or in the mice infected by replication competent retroviruses, such as 
Moloney Murine Leukemia Virus (MoMuLV) (Nakamura, 2005; Jonkers and Berns, 
1996). 
Cooperative genetic alterations might be identified using a simple insertional 
mutagenesis model. However, a more efficient device is needed to clarify cooperative 
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genes for particular genes. RIM on genetically engineered animal models that are 
predisposed to tumor formation is therefore a good method for identification of 
cooperative genes of the primary genetic defect in these animals. When the cells, which 
already have primary genetic abnormality, receive additional genetic alterations by 
retroviral insertion and develop cancer, then the integration serves to add specific 
cooperative genetic changes, or “second hit”, for the primary alterations (Nakamura, 
2005; Yanagida et al., 2005; Yamashita et al., 2005). In other words, a gene can be 
defined as a putative cooperating gene if it is more frequently targeted in mice with 
specific genetic background compared to wild type under the same retroviral insertional 
stress. I have applied this RIM method on Runx1 conditional knockout mice models to 




Fig. 1.11: RIM of host genes 
Structural features of an integrated provirus and different modes of proviral 
activation/inactivation of a hypothetical target gene. Colored boxes on DNA represent 
exons and their transcripts are depicted below on RNA. (Modified from Jonkers and 
Berns, 1996) 
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1.7. Aims of the project 
It is clear that loss-of-function of RUNX1 contributes to the pathogenesis of RUNX1 
related leukemia, as discussed in the previous section. On the other hand, it is equally 
obvious that RUNX1 alteration alone is insufficient for development of full blown 
leukemia and these alterations probably only result in a preleukemic state.  
This leads us to the first question to decipher the mechanism of RUNX1 related 
leukemia. Why is loss-of-function of RUNX1 preleukemic and not completely 
leukemogenic? The conditional Runx1 knockout mice provide an excellent model to 
answer this question. The Runx1 gene is knocked out in the mice after they reach 
adulthood and therefore, these mice probably recapitulate the state of loss-of-function of 
RUNX1 in humans. The first aim of my project is to gain an understanding of why loss-
of-function of Runx1 is only preleukemic and does not result in full blown leukemia, 
using hematopoietic cells from BM of conditional Runx1 knockout mice.   
The next question is how does loss-of-function of Runx1 finally result in 
leukemia? The general consensus is that additional genetic alterations are required for 
leukemia development. Therefore, the second aim of my project is to identify genetic 
alterations that may cooperate with Runx1 deficiency in leukemogenesis, especially 
genetic alterations that help to overcome the inherent defect in Runx1 deficient cells that 
prevent them from developing full blown leukemia. To address this question, I employed 
RIM on conditional Runx1 knockout mice. 
The final aim is to verify the cooperation between Runx1 deficient status and 
identified genetic alterations in the initiation and/or progression to leukemia and gain 
some mechanistic understanding of this cooperation. 
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Chapter 2 - Materials and Methods 
 
Generation of mice 
The mice harboring Runx1 alleles flanked by loxP sites were generated by Ichiro 
Taniuchi et al (2002).  Runx1F/+ mice were backcrossed against C57BL/6 mice for 3 
generations, and then intercrossed to obtain Runx1F/F mice. They were crossed with 
interferon-inducible Mx-Cre (myxovirus resistance 1 gene promoter driven Cre 
recombinase) transgenic mice (Kuhn et al., 1995), a gift from Dr. K. Rajewsky, to 
generate Runx1F/F— Tg(Mx1-Cre) mice. Runx1F/F—Tg(Mx1-Cre) mice were then mated 
to Runx1F/F mice to generate Runx1F/F—Tg(Mx1-Cre) and Runx1F/F littermates for various 
experiments. In Runx1F/F—Tg(Mx1-Cre) mice, exon 4 encoding part of Runt domain on 
both alleles can be deleted by conditionally expressed Cre-recombinase.  
For RIM experiments, Runx1F/F—Tg(Mx1-Cre) mice were mated with Runx1F/F 
mice and progenies were intraperitoneally injected with Moloney Murine Leukemia 
Virus (MoMuLV) 3 days after birth. They were genotyped by PCR at the age of one 
month, using their tail genomic DNA extracted by Direct PCR Lysis Reagents (Viagen 
Biotech, USA) as template. One month after birth, mice were subjected to 600 μg of 
polyinosinic-polycytidylic acid (pIpC; Sigma, USA) intraperitoneal injection on seven 
alternate days for excision of the floxed alleles with greater than 90% efficiency 
(Growney et al., 2005). For other experiments, to obtain conditional Runx1 knockout and 
wild type littermate control BM, progenies of Runx1F/F—Tg(Mx1-Cre) and Runx1F/F 
parents were genotyped after a month and subjected to pIpC treatment as described above 
at one month of age or later when required. pIpC treated mice were checked for the 
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deleted Runx1 alleles by PCR using their PB DNA one month after the final pIpC 
injection. All mice were maintained in Biological Resource Center (BRC), Biopolis, 
Singapore and all animal experiments followed the strict guidelines set by National 
Advisory Committee for Laboratory Animal Research (NACLAR). 
 
Hematological analysis 
Retrovirus injected conditional Runx1 knockout mice and wild type littermates were 
monitored for the development of leukemia by examining their health condition and by 
weekly checking of complete blood cell count (CBC) by an automatic hematology 
analyzer (Celltac alpha MEK-6358, Nihon Kohden, Japan). Severely moribund mice, 
often with a rapid elevation of leukocyte count, were euthanized and subjected to 
necropsy. Abnormalities in hematopoietic tissues were recorded as follows: enlargement 
of the thymus, liver, and spleen, and swelling of lymph nodes. Leukemic cells from the 
PB, BM and spleen were subjected to May-Giemsa staining. Immunophenotypic analysis 
of leukemic cells was carried out by flow cytometry. The following antibodies 
(Pharmingen, San Diego, CA, USA) were used: PE – conjugated Mac1 (M1/70), c-Kit 
(2B8), Fas (MFL3), CD3(145-2C11), CD8 (53-6.7), TCRδ (GL3)  (Caltag Labs, 
Burlingame, CA, USA), CD44 (IM7), CD61 (2C9.G2), Ter119 (TER-119) and  FITC – 
conjugated Gr1 (RB6-8C5), CD34 (RAM34), CD4 (RM4-5), TCRβ (H57-597), CD25 
(7D4), B220 (RA3-6B2), CD19 (1D3), CD41 (MWReg30) and CD71 (C2). low 
cytometry analysis was performed using a fluorescence activated cell sorting (FACS) 
vantage instrument with the Cellquest program (Becton Dickson, USA) after addition of 
2 mg/ml of propidium iodide (PI; Sigma) to exclude dead cells. 
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Identification of retroviral integration sites by inverse PCR  
In all, 5 μg of genomic DNA extracted from mouse leukemic cells from the spleen or 
thymus was digested by BstYI and self circularized overnight by T4 DNA ligase (New 
England Biolabs, Inc., MA, USA) at 16oC. Then, 5’ and 3’ integration flanking fragments 
were amplified individually by iPCR. The first PCRs were performed with AccuPrime 
Taq (Invitrogen life technologies, Carlsbad, CA, USA) employing an initial preheating 
step at 95°C for 5 min followed by 30 cycles of 95°C for 1 min, 60°C  for 1 min and 
68°C for 3 min. The second PCRs were performed by rTaq (Promega, Madison, WI, 
USA) employing an initial preheating step at 95°C for 5 min followed by 35 cycles of 
95°C for 1 min, 55°C for 1 min and 68°C for 2 min. The amplified PCR products were 
cloned by the TA cloning method using the plasmid pGEM-T vector (Pharmingen Co, 
Madison, WI, USA) and subjected to cycle sequencing (Applied Biosystems, Foster City, 
CA, USA) using the M13-Reverse primer. The position mapping of the RIS on the mouse 
chromosome was performed by BLAT searching of the UCSC Genome Bioinformatics 
database (http://genome.ucsc.edu). The definition of a common integration site (CIS) was 
the same in the retroviral-tagged cancer gene database (RTCGD) 
(http://RTCGD.ncifcrf.gov); each window size is 100, 50, or 30 kb for CIS with four (or 
more), three, or two insertions, respectively, in each model (Akagi et al., 2004). 
 
Plasmid construction 
The MIG retroviral vector (MSCV-IRES-GFP) was used for cloning human GFI1, EVI5 
and EVI1. The MIG vector is composed of MSCV (murine stem cell virus) LTRs (long 
terminal repeat), IRES (internal ribosome entry site) and EGFP (enhanced green 
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fluorescent protein) gene. Human EVI5 and GFI1 fragments were amplified by PCR 
method using Accuprime Taq (Invitrogen, USA) and template complementary DNAs 
(cDNA) from U937 cell line. The PCR was performed using gene specific primers 
complimentary to the ends of the gene with EcoRI recognition sequence attached to 
forward primer and NotI recognition sequence attached to reverse primer. PCR cycling 
conditions included preheating step at 95°C for 5 min followed by 35 cycles of 95°C for 
30 sec, 58°C for 40 sec and 68°C for 3 min, and a final extension step at 68°C for 10 min. 
The PCR products were purified by QIAquick PCR Purification Kit (QIAGEN, 
Germany), digested with EcoRI and NotI and cloned into similarly digested MIG vector 
using standard protocol. The sequence of each clone was verified by cycle sequencing 
(Applied Biosystems). Human EVI1 construct was a gift from Dr. K. Moroshita. The 
EVI1 gene was subcloned into the MIG vector after restriction digestion from the original 
construct.  All the amplified vector plasmids were purified by EndoFree Plasmid Maxi kit 
(QIAGEN GmbH, Germany).  
 
Packaging cell line and retroviral transduction 
Phoenix-Eco packaging cell line was kindly provided by Dr. G. P. Nolan. The cells were 
selected by Hygromycin B (0.36 units/ml) and diphtheria toxin (1 mg/ml) (Calbiochem, 
San Diego, CA, USA) in low glucose Dulbecco’s Modified Eagle Medium (DMEM) 
(Gibco, USA) supplemented with 10% fetal bovine serum (FBS) (Hyclone, USA) and 1% 
antibiotic-antimycotic (Gibco) for one to two weeks. Two 100 cm dishes of selected cells 
were transiently transfected with 120 μg of each constructed plasmid using Fugene 
(Roche, Mannheim, Germany). The medium was changed to high glucose DMEM 12 
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hours after the transfection. The supernatant containing retrovirus was collected twice, at 
36 hours and 60 hours after transfection and centrifuged at 8000 rpm (revolutions per 
minute) at 4°C for 12 hours and resuspended in 1 ml of Minimum Essential Medium 
alpha Medium (αMEM) (Gibco) containing 10% FBS and 1% antibiotic-antimycotic. 500 
μl of virus solution was added together with 25-50 μg/ml of Retronectin (TAKARA, 
Japan) to 1-2.5 x 106 BM cells pre-cultured under cytokine stimulation as described 
below. Two rounds of spin infection of target cells were performed at 2000 rpm at 30°C 
for two hours, one after each harvest of retrovirus. Subsequently the plate was re-cultured 
at 37°C. The virus transfected BM cells were harvested 24 hours after the second spin 
infection (i.e. 48 hours after the first spin infection) for further experimental use. 
 
Bone marrow cells collection 
For the experiments using BM cells, the host mice were injected with 2.5 mg of 5-FU 
(five fluorouracil; Sigma) per 500 μl of phosphate buffered saline (PBS) per mouse five 
days prior to the BM collection to get the best yield of stem/progenitor cell fraction. BM 
cells were collected from four limbs of each mouse by flushing media through the 
marrow of the bones. The RBC were first lysed by lysis buffer (150 mM NH4Cl, 10 mM 
KHCO3, 0.1 mM Na2EDTA), remaining BM cells washed with cold PBS and 
resuspended in αMEM supplemented with 10% FBS and 1% antibiotic-antimycotic. In 
the experiments using retrovirally transfected BM cells, 1-2.5 x 106 cells were cultured in 
1.5 ml of αMEM supplemented with 10% FBS, 1% antibiotic-antimycotic and 10 ng/ml 
recombinant murine interleukin-3 (IL-3), 20 ng/ml interleukin-6 (IL-6) and 10 ng/ml 
stem cell factor (SCF) (all cytokines are from Pepro Tech EC Ltd, USA) per well of a 6 
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well plate. BM cells were preincubated for 24 hours before the first spin infection of 
retrovirus. 
 
Bone marrow transplantation (BMT) 
BM cells collected from pIpC treated Runx1F/F—Tg(Mx1-Cre) and Runx1F/F mice were 
transfected with MIG vector containing gene of interest. After one day of culture 
following spin infection, the cells were collected in αMEM media and 5 x 105 cells were 
transplanted into sublethally (6 Gy) irradiated recipient C57BL/6 mice around 8 weeks 
old which were given acid water one week prior to irradiation. GFP+ cells were not 
selected after the transduction protocol, so transplants consisted of a mixture of 
transduced and nontransduced cells. Transplanted recipient mice were monitored at least 
once a week and at several points after transplantation, blood was drawn from the retro-
orbital plexus and total cell numbers were counted. The reconstitution ability of donor 
cells was also assessed at the same time points by flow cytometric analysis of GFP+ cells 
in PB.  
 For serial BMT experiments, initial steps were similar to that described above. A 
mixture of 5 x 105 transfected and non transfected BM cells were transplanted into 
sublethally (8 Gy) irradiated primary recipients.  At an average of 4 months after primary 
transplantation, the primary recipients were sacrificed and BM cells extracted. BM cells 
were processed to eliminate RBCs by lysing, following which 5 x 105 cells were 
immediately transplanted into sublethally (8 Gy) irradiated secondary recipients. Survival, 
PB counts and percentage of GFP positive cells in the blood were monitored at regular 
intervals after transplantation.  
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In vivo homing assay 
BM cells from pIpC treated Runx1F/F—Tg(Mx1-Cre) and Runx1F/F mice were isolated 
from hind/forelimbs by flushing, followed by RBC lysis. The BM cells were stained with 
2.0 μM carboxy fluorescein diacetate, succinimidyl ester (CFSE) (Molecular 
Probes/Invitrogen, Carlsbad, CA) at a concentration of 106 cells/ml for 15 min at 37°C, 
washed, and further incubated at 37oC for 30 min in cell culture medium, according to 
manufacturer’s instructions. 5 x 106 stained cells were then transplanted into lethally 
irradiated (10 Gy) recipient mice. 16 hours after transplantation, BM cells were isolated 
from recipients and directly analyzed on a FACS vantage.  
 
Flow cytometric analysis  
For flow cytometric analyses, BM cells either directly collected from mice or harvested 
after viral transfection, were preincubated with mouse serum for 15 min on ice before 
staining. The antibody reaction was carried out in the mouse serum for additional 15 min 
on ice. All the labeled monoclonal antibodies were purchased from BD PharMingen, 
USA. For c-Kit single staining and analysis/sorting, PE-conjugated anti-c-Kit (2B8) was 
used. For KSL CD34 fraction analysis, the following antibodies were used: PE-
conjugated anti-Gr1 (RB6-8C5), Mac-1 (M1/70), Ter119 (TER-119), CD4 (RM4-5), 
CD3 (145-2C11), CD8 (53-6.7), B220 (RA3-6B2), IL7Rα (SB/199), APC-conjugated 
anti-c-Kit (2B8), APC-Cy7 conjugated anti-Sca-1 (E13-161.7) and FITC-conjugated 
CD34 (RAM34). Flow cytometric analysis was performed using FACS vantage 
instrument with the Cellquest program after addition of 2 mg/ml of propidium iodide to 
exclude dead cells.  
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Long-term culture-initiating cell (LTC-IC) assay 
BM cells collected from pIpC treated Runx1F/F—Tg(Mx1-Cre) and Runx1F/F were 
transfected with mock MIG vector or MIG vector containing gene of interest and sorted 
for c-Kit+GFP+ fraction using FACS vantage. 104 sorted cells were cultured on OP9 
stromal cells per well in a 6-well plate in 2 ml of αMEM media supplemented with 10% 
FBS, 1% antibiotic-antimycotic and 10 ng/ml recombinant murine IL-3, 100 ng/ml G-
CSF, 10 ng/ml SCF and 10 ng/ml EPO (Pepro Tech EC Ltd). Twice a week, 500 μl of 
medium with original concentration of cytokines was supplemented into each well. Every 
fourteen days, the floating cells were collected and the well was refilled with fresh 
cytokines/medium. On day 30, OP9 stromal cells together with adherent hematopoietic 
cells were trypsinized and harvested, resuspended in 1 ml of αMEM containing 10% FBS 
and 1% antibiotic-antimycotic. The harvested cell suspension was replated in a new well 
and was incubated at 37°C for 30 min to 45 min. This procedure allows the OP9 cells to 
adhere to the bottom of the culture dish first, so that floating hematopoietic cells can be 
separately collected. These floating hematopoietic cells collected from each well were 
then subjected to colony-forming unit-culture (CFU-C) assays and another round of long 
term culture on OP9 stromal cells for 30 days. 
 
Colony-forming unit-culture (CFU-C) assay 
104 cells were cultured in 35-mm dishes in either duplicate or triplicate in 1 ml Methocult 
M3131 methylcellulose medium (StemCell Tec., Canada) containing 1% antibiotic-
antimycotic supplemented with 10 ng/ml recombinant murine IL-3, 10 ng/ml SCF, 100 
ng/ml G-CSF and 10 ng/ml EPO. The dishes were cultured at 37°C. Colony formation 
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(one colony consists of more than 30 cells) was scored on day 10. For serial replating 
assays, colonies were harvested in cold PBS, centrifuged at 1500 rpm for 5 min to collect 
cells and colony assay was repeated using 104 cells for next round.  
 
Luciferase Assay 
The luciferase reporter plasmid PGL3-CXCR4 promoter (860 bp)-luc was a gift from Dr. 
Wilhelm Krek. The reporter plasmid (0.2 μg) and the effector plasmids, pEF-RUNX1 
(0.2 μg), pEF-R174Q (0.2 μg) and pEF-PEBP2β (0.1 μg) were transfected into HL60 
cells by a nonliposomal transfection reagent, FuGENE6 (Roche). The transfected cells 
were incubated for 48 hours and assayed for luciferase activity as previously described 
(Osato et al., 1999). 
 
Quantitative real-time PCR (qRT-PCR) 
The cKit+GFP+ fraction of BM cells transduced with MIG vector was sorted by FACS 
directly into TRIZOL LS Reagent (Invitrogen, USA). RNA extraction was performed 
following the manufacturers instruction. cDNA was synthesized by Expand Reverse 
Transcriptase (Roche Molecular Biochemicals) and subjected to qRT-PCR. The real-time 
PCR was performed using ABI prism 7900HT (Applied Biosystems) with an initial step 
of 95°C for 10 min followed by 40 cycles of 94°C for 15 sec and 60°C for 1 min. The 
specific primers and TaqMan probes were purchased from Applied Biosystems. All the 
reactions were performed in triplicate. Relative quantity of expression was calculated by 
SDS software ver.2.2.2 using Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) as an 
endogenous internal control. 
 56
Cytospin preparation 
5 – 10 x 104 cells per well were cytospun using a cytocentrifuge (Cytospin4, Thermo 
Shandon, USA) on a slide. The slides were first stained with May-grunwald stain solution 
(May-grunwald solution (BDH, UK) : Methyl Alcohol = 1:3) for 5 min. After running off 
the solution, the slides were stained with Giemsa stain solution (Giemsa solution (BDH): 
phosphate buffer (pH 6.4, KH2PO4 6.63 g, Na2HPO4 2.56 g / 1000 ml) = 1:20) for 30 








Chapter 3 - Results 
 
Runx1 knockout stem/progenitor cell expansion is followed by stem cell exhaustion  
Loss-of-function of RUNX1 is frequently seen in human AML, especially in adults. 
However, RUNX1 alteration alone is considered to be preleukemic rather than fully 
leukemogenic. Conditional deletion of Runx1 in adult mice provides a good animal 
model system to understand the consequence of loss-of-function in hematopoiesis and 
leukemogenesis. Of special interest is the effect of Runx1 alteration on the hematopoietic 
stem/progenitor cell compartment since this population of cells seems to be the main 
target of oncogenic events that could give rise to leukemia. Hence, analyses of the short 
term and long term effects of Runx1 deficiency in hematopoietic stem/progenitor cells of 
conditional Runx1 knockout mice could shed some light on preleukemic effects of loss-
of-function of Runx1 and additional steps that are required for full blown leukemogenesis. 
 Runx1 null BM cells generated by Cre-recombinase-mediated knock-out of 
Runx1 (referred to as Runx1-/- in this thesis) show an increase in hematopoietic 
stem/progenitor cell fraction (Growney et al., 2005; Ichikawa et al., 2004; Putz et al., 
2006) . There is more than two fold increase of the c-Kit+Sca1+Lin- (KSL) stem cell 
fraction and c-Kit+Sca1-Lin- progenitor cell fraction in Runx1-/- mice, compared to wild 
type littermates (referred to as Runx1+/+ in this thesis). Despite the increased number of 
stem cells, Growney et al. reported that Runx1-/- BM cells are outcompeted by 
simultaneously transplanted wild type BM cells in competitive repopulation assay, 
indicating that Runx1-/- cells are compromised in reconstituting hematopoiesis in the 
recipient mice.  
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I observed similar results in our laboratory. Recipient mice were transplanted with 
BM cells from Runx1-/- and Runx1+/+ mice transfected with retroviral vector expressing 
EGFP as a surrogate marker. Contribution of donor Runx1+/+ and Runx1-/- cells to 
hematopoiesis in recipients was monitored periodically by checking the percentage of 
GFP positive cells in the PB, hereafter referred to as GFP chimerism. Runx1+/+ BM cells 
showed stable contribution to hematopoiesis in recipients throughout while Runx1-/- BM 
cells showed decreasing contribution progressively. Six weeks after transplantation, the 
GFP chimerism in PB of the recipients that received Runx1+/+ cells was similar to that 
of the recipients of Runx1-/- cells with a mean value of 32.1% and 23.6% respectively in 
a cohort of 6 recipient mice. After 40 weeks, the mean GFP chimerism in recipients of 
Runx1+/+ cells remained the same, at 32.5%; however, the GFP chimerism in the 
recipients of Runx1-/- cells progressively decreased and by 40 weeks after transplantation, 
it was significantly lower than that in the recipients of  Runx1+/+ BM cells, with a mean 
of  13.1% (Figure 2.1).  
 
By 2 years after transplantation, the GFP chimerism in PB of recipients of Runx1-
/- cells had dropped even more significantly and the difference between GFP chimerism 
of recipients of Runx1-/- cells and Runx1+/+ cells was more pronounced (Figure 2.2A). 
There was also a concomitant decrease in absolute number of immature (ckit+Lin-) 
Runx1-/- cells in the BM of the recipients, indicating lower number of Runx1-/- stem cells, 
which may explain the decreasing reconstitution of hematopoiesis (Figure 2.2B). This 


















































Figure 2.1: Runx1-/- stem cells are impaired in long term reconstitution of 
hematopoiesis   
GFP chimerism in PB of recipients of Runx1+/+ (n=6) and Runx1-/- (n=6) cells 6 and 40 
weeks after transplantation. Each open circle represents data from an individual mouse 
and closed red circle is the average of a cohort. Stastical difference using unpaired 





However, surprisingly, colony assay of immature (c-Kit+Lin-GFP+) Runx1-/- and 
Runx1+/+ cells from the BM of recipient mice showed that they were functional even 2 
years after transplantation. In fact, immature Runx1-/- cells formed higher number of 
colonies than immature Runx1+/+ cells, similar to the observations soon after the 
conditional deletion of Runx1 gene by pIpC injection (Figure 2.2C). This indicates that 
immature Runx1-/- cells maintain their inherent properties of increased proliferation even 
after long periods of time, suggesting that stem cell exhaustion of Runx1-/- cells may not 

































































































































Figure 2.2: Immature Runx1-/- cell numbers decrease progressively, resulting in 
lower reconstitution of hematopoiesis, but they form higher number of colonies   
Analysis of recipients of Runx1+/+ and Runx1-/- BM cells 2 years after transplantation - 
Graphs showing (A) percentage of GFP+ cells in PB; (B) numbers of GFP+cKit+Lin- 
cells in BM; and (C) colony assay of GFP+cKit+Lin- cells from the recipient BM. 





Serial transplantation experiment was then carried out to confirm if the Runx1-/- 
stem cells undergo exhaustion and are impaired in long term reconstitution of 
hematopoiesis. Runx1+/+ and Runx1-/- BM cells were transfected with MIG vector and 
transplanted into sublethally irradiated (8 Gy) primary recipients. GFP chimerism was 
monitored for an average of 4 months in these recipients. Following that, two to three 
primary recipients with similar GFP chimerism were sacrificed; and BM cells were 
transplanted into 10 sublethally irradiated (8 Gy) secondary recipients. 6 out of 10 
recipients of Runx1-/- cells died within three months of secondary transplantation, while 
all the recipients of control Runx1+/+ cells are alive to date (Figure 2.3). This result 



























indicates that Runx1-/- stem cells are impaired in reconstituting hematopoiesis in the 
secondary recipients and majority of them die due to pancytopenia; unlike Runx1+/+ 
stem cells which are capable of reconstituting hematopoiesis in the secondary recipients. 


















Figure 2.3: High mortality in secondary recipients of Runx1-/- BM cells  
Kaplan-Meier survival curves of secondary recipients of mock MIG vector transfected 
Runx1+/+ (blue line; n=10) and Runx1-/- (red line; n=10) BM cells, 4 months after 





BMT of cells from aged Runx1-/- and Runx1+/+ mice also lends support to the 
above observations. BM cells obtained from Runx1F/F— Tg(Mx1-Cre) mice 6 months 
after conditional deletion of Runx1 by pIpC injection and similarly treated wild type, 
Runx1F/F, littermates were transplanted into sublethally irradiated (8 Gy) recipients (n = 4 
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to 5) and GFP chimerism of PB was assessed at selected time points. The GFP chimerism 
in PB of recipients of Runx1-/- cells (average of 38.2%) was significantly lower than that 
of the recipients of Runx1+/+ cells (average of 61.3%) right from the first time point 
which was 4 weeks after transplantation (Figure 2.4). Lower GFP chimerism of Runx1-/- 
cells was also seen during subsequent time points such as 6 and 8 weeks after 
transplantation. In few of the recipient mice that were sacrificed and analyzed 2 months 
after transplantation, the GFP chimerism in BM was also significantly lower in the 
recipients of Runx1-/- cells than Runx1+/+ cells. This indicates that in aged Runx1-/- 
mice, the stem/progenitor cells are already slowly undergoing the process of exhaustion 
as a result of which, they cannot repopulate the recipient mice like stem cells from 
Runx1+/+ mice or younger Runx1-/- mice.  
We further investigated the frequency of long term (LT) and short term (ST) HSC 
in Runx1+/+ and Runx1-/- KSL fraction by checking CD34 expression. Only CD34- LT-
HSC, but not CD34+ ST-HSC, amongst KSL fraction are believed to be quiescent and 
capable of long term reconstitution of hematopoiesis (Osawa et al., 1996). Consistent 
with our data indicating stem cell exhaustion, there was a shift in Runx1-/- KSL cells 
towards CD34+ ST-HSC fraction while Runx1+/+  KSL cells showed both CD34- (LT-
HSC) and CD34+ (ST-HSC) peaks (Figure 1D). The average percentage (n=4) of CD34- 



























































Figure 2.4: Early defects in hematopoietic reconstitution by aged Runx1-/- cells  
Graph showing reconstitution of recipients by BM cells from aged Runx1+/+ (n=4) and 
Runx1-/- (n=5) mice four weeks after transplantation.  Each open circle represents data 











Figure 2.5: Quiescent LT-HSC are reduced in Runx1-/- mice 
Expression of CD34 in KSL gated fraction of Runx1+/+ (blue) and Runx1-/- (red) BM 
cells. One representative result out of 4 is shown. 
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All the above results taken together show that though there is an initial expansion 
of Runx1-/- stem/progenitor cells as has been previously reported by various groups, the 
expansion seems to be transient as this is followed by Runx1-/- stem cell exhaustion. The 
decreasing contribution of Runx1-/- stem cells in primary recipients and the inability to 
reconstitute hematopoiesis in secondary recipients confirm this phenomenon of stem cell 
exhaustion. Thus, although Runx1 alteration leads to a transient increase in 
stem/progenitor cell numbers the development of leukemia from these aberrant stem cells 
may require accumulation of additional genetic alterations that prevent stem cell 
exhaustion and maintain the aberrant cells. To this end, I used RIM on conditional Runx1 
knockout mice to identify additional genetic alterations that cooperate with loss-of-
function of Runx1 in leukemogenesis.  
 
 
Runx1-/- mice are more susceptible to leukemia development than wild type mice 
I employed RIM to induce leukemia in Runx1-/- mice and control Runx1+/+ littermates to 
study susceptibility of these mice to leukemia and to fish out candidate cancer genes 
involved in Runx1 related leukemia with loss-of-function of Runx1. Lymphotropic 
murine leukemia virus, MoMuLV, which can integrate randomly into the host genome, 
was injected into Runx1-/- mice and wild type littermates. The retroviral insertion into 
host genome may result in activation of host oncogenes or disruption of tumor 
suppressors as a consequence of which mice develop leukemia/lymphoma. Interestingly, 
Runx1-/- mice showed significantly shorter latency of tumor development than wild type 







































Figure 3.1: Runx1-/- mice show higher incidence and earlier onset of tumor 
Kaplan Meier survival curves of Runx1+/+ (blue line; n=17) and Runx1-/- (red line; 
n=16) mice injected with MoMuLV retrovirus. Kaplan–Meier method showed significant 





When the mice became moribund, they were sacrificed and subjected to necropsy. 
PB cell counts were measured and abnormalities in hematopoietic tissues were recorded 
as follows: enlargement of the thymus, liver, and spleen, and swelling of lymph nodes. 
Based on necropsy, the cancer disease was divided into leukemia or lymphoma cases. 
Leukemia cases showed elevated blood cell counts and only splenomegaly with normal 
thymus/lymph nodes, while lymphoma cases showed normal or mildly elevated blood 












Figure 3.2: Necropsy of mice with leukemia or lymphoma 
Leukemia mice usually show enlarged spleen and liver while lymphoma mice usually 
show enlarged thymus. Enlarged spleen may also be found in some lymphoma cases.  
 
 
Immunophenotypic analysis was done using FACS analysis to check for the 
presence of cell surface markers for immature cells, myeloid cells, and T- and B-cells. 
Leukemic cells from the PB, BM and spleen were subjected to May-Giemsa staining for 
morphological analyses. Based on combination of leukocyte counts, necropsy, 
immunophenotype and morphological analyses, tumors were classified into the following 
4 groups (Figure 3.3) 
1. Group 1 - Leukemia with myeloid features alone; shows elevated blood cell count, 
splenomegaly, myeloid cell morphology and expression of myeloid antigens. 
Leukemia onset is within 24 weeks after birth, early onset. 
2. Group 2 - Leukemia with T-cell and myeloid features; shows elevated blood cell 
counts, splenomegaly and immature/myeloid/T-cell morphology. At least majority of 
these leukemias are biphenotypic as they express high percentage of both myeloid 







3. Group 3 - Leukemia with T-cell features alone; shows elevated blood cell counts, 
splenomegaly, slight enlargement of thymus in some cases, T-cell morphology and 
expression of T-cell antigens. Leukemia onset can be early (<28 weeks) or late (>28 
weeks). 
4. Group 4 – Lymphoma; shows normal or mildly elevated blood cell counts and 
significant enlargement of thymus and/or lymph node due to accumulation of T-cells 
and expression of T-cell antigens. Onset of lymphoma can be early (<28 weeks) or 
late (>28 weeks).  
Majority of the Runx1-/- mice developed early onset leukemia with myeloid 
features that fell into group 1 and 2 or early onset leukemia/lymphoma that fell into group 
3 and 4. Most of the Runx1+/+ mice developed T-cell leukemia/lymphoma that belonged 
to group 3 and 4, with varying onset times (Figure 3.3). This indicates that Runx1 
knockout status drives myeloid tropism despite the strong T-lymphotropism of MoMuLV 
virus. Some of the group 1 and 2 leukemias recapitulated human RUNX1 related 
leukemias with accumulation of immature blasts (as seen in AML M0) or accumulation 
of myeloid cells with slight differentiation (as seen in AML M2 ) (Figure 3.4).  
The fact that Runx1-/- mice showed significantly earlier onset and higher 
incidence of leukemias with myeloid features (group 1 and 2) indicates that they are more 
susceptible to leukemia development and the retroviral integration sites (RIS) in these 
mice could cooperate with Runx1-/- status in the development of leukemia with myeloid 
features. Some of these genetic alterations may aid in leukemia progression by preventing 
exhaustion of Runx1-/- stem cells and maintaining the abnormal cells in the individual 
mice till they become completely leukemogenic. Identification and analysis of the viral  
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Figure 3.3: Runx1-/- mice develop early onset leukemia with myeloid features 
(A) Graph showing frequency of different types of leukemia/lymphoma, groups 1-4, in 
early onset (≤ 24 weeks) cancers of Runx1+/+ (n=19) and Runx1-/- (n=34) mice. (B) 
Graph showing frequency of leukemia or lymphoma cases in late onset cancers of 
Runx1+/+ (n=33) and Runx1-/-(n=20) mice. In total, n=52 for Runx1+/+ mice and n=54 
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Figure 3.4: Morphology of Runx1-/- leukemic cells recapitulates human leukemias 
Morphology of cells from PB of representative leukemic case from (A) Group 1 showing 
granulocytes (arrow) and monocytes (arrowhead) (B) Group 2 showing immature blasts 
and (C) Group 3 showing T-cells and ghost cells (arrows) which are frequently seen in T-
cell malignancy.  
 
 
Immature blasts T-cells Myeloid cells 
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integration sites may shed some light on genetic alterations that cooperate with loss-of-
function of Runx1 by preventing stem cell exhaustion or other mechanisms, thus aiding 
the progression of Runx1 deficient cells from preleukemic state to full blown leukemia. 
 
Stemness related genes are preferentially affected in Runx1-/- mice  
An individual tumor (leukemia/lymphoma) induced by MoMuLV virus had 4 to 10 
retroviral integration sites, suggesting that by the time a mouse develops leukemia, 
sufficient number of genes are activated or inactivated that cooperate with each other or 
the background (Runx1-/- status) to induce full blown leukemia/lymphoma. To identify 
the retroviral integration sites (RIS) in the Runx1-/- and Runx1+/+ mice, the genomic 
DNAs extracted from their leukemic cells were subjected to an iPCR method after BstYI 
digestion (Yanagida et al., 2005). I found 710 integration flanking sequences (tags) in 63 
Runx1-/- mice and 52 Runx1+/+ mice. These sequences were mapped to the mouse 
genome to identify the chromosomal location of the sequence and to identify candidate 
genes at that locus. 20 loci were affected more than once by retroviral integrations in 
Runx1-/- or Runx1+/+ mice and these are referred to as CIS which are considered to be 
near candidate leukemogenic genes (Table 2). The relative locations of these integration 
sites were compared to the tags from the publicly available retroviral-tagged cancer gene 
database (RTCGD) (Akagi et al., 2004). This comparison revealed that 15 of the CIS 
correspond to previously known loci where retroviral integration occurred more than 
once. In addition, five CIS that have been identified only by our study and hence have 
been designated as Slis (Singapore leukemia integration site) were classified as novel CIS 
(Table 2).   
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 Classification of RIS Chromosome  Gene b Runx1 +/+ Runx1 -/- 
   Number a   n=52 n=63 
Known CIS (15)c     
 5 Gfi1/Evi5 2 11 (3)d 
 15 Myc 3 11 
 17 Ccnd3 2 6 
 7 RRas2 4 5 
 10 Ahi1/Myb 7 3 
 2 Rasgrp1 2 2 
     
         
 3 Evi1 0 5 
 6 Ccnd2 0 3 
 12 Nmyc 0 3 
 17 Pim1 0 3 
 2 Bcas1 0 2 
 5 Bcl7a 0 2 
 7 Sema4b 0 2 
 12 Jundm2 0 2 
 11 Ikaros 0 2 
          
Novel CIS (5)c X SlisX 0 4 
 3 Slis6 0 3 
 5 Slis7 0 2 
 16 Slis9 0 2 
  5 Mad1l1 0 2 
 
CIS, common integration site; RIS, retroviral integration site 
 
Table 2: Classification of RIS identified in Runx1+/+ and Runx1-/- leukemias 
a The genomic positions of the RIS were determined according to BLAT searching of the 
UCSC Genome Bioinformatics database. b Candidate genes in the vicinity of the RIS are 
shown. Number in parentheses indicates c number of known and novel CIS and d number 
of integrations inside the Evi5 gene. The bold rows indicate the particularly interesting 
CIS that are discussed in the text.  
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The CIS that have been repeatedly identified in the same cancer model are assumed to be 
more significant candidate genes with regard to the pathogenesis of the specific type of 
cancer in question. It is of special interest to note the genes that were hit with high 
frequency in Runx1-/- mice, but not affected or affected with lower frequency in 
Runx1+/+  mice, because they may be specifically involved in leukemogenesis of Runx1-
/- mice. Integrations at the Gfi1/Evi5 locus were found in 11 out of 63 Runx1-/- mice 
analyzed while only 2 Runx1+/+ mice out of 52 showed integrations at this locus (Figure 
4.1; purple and blue arrows respectively). More than half the integrations, 8 out of 13, 
were in between the Gfi1 and Evi5 genes, 3 were inside the Evi5 gene, one inside Gfi1 
and one downstream of Gfi1. 7 of the Runx1-/- leukemia cases with integrations at the 
Gfi1/Evi5 locus belonged to group 1 and 2 which showed early onset leukemia with 
myeloid features. Thus, 7 out of the 18 Runx1-/- leukemia cases (approximately 40%) in 
group 1 and 2 had integrations at Gfi1/Evi5 locus. The remaining 4 mice with integrations 
at Gfi1/Evi5 locus could not be classified due to unavailability of morphology and 
immunophenotype data, but they could belong to group1 and 2 since they showed early 
onset of leukemia and there was no enlargement of thymus/lymph node (Table 3).  
Gfi1 (Growth Factor Independent 1), is a well known factor involved in stem cell 
maintenance. In the absence of Gfi1, stem cells lose their repopulating ability and cannot 
maintain normal stem cell functions  (Hock et al., 2004). Evi5 was shown to be a cell 
cycle regulator required for stabilizing key proteins such as Emi1 which inhibits 
Anaphase Promoting Complex (APC) and prevents premature entry  of cells into mitosis 
(Eldridge et al., 2006). The role of Evi5 in stemness has not been investigated to date.  In 
order to clarify which of the two genes, Gfi1 or Evi5 may be altered by integrations at the 
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Gfi1/Evi5 locus in Runx1-/- mice, I carried out expression check using qRT-PCR on 
cDNA from 6 of the available leukemic samples from group 1 and 2 with integrations at 
this locus and 3 control samples with no integration at this locus. Evi5 overexpression 
was seen in all affected Runx1-/- cases with integration outside the gene, compared to the 
three control cases (Figure 4.2). Moreover, expression of Evi5 increased proportionately 
as the distance between the viral integration site and the Evi5 gene decreased, indicating 
specific, integration site dependant alteration of Evi5 expression. Integrations inside the 
Evi5 gene did not alter expression of the gene. In contrast to Evi5, Gfi1 expression was 
not significantly affected by viral integrations in most leukemia cases. They showed 
similar expression levels of Gfi1 as the three controls (Figure 4.2).  
Out of the integrations that were present only in Runx1-/- mice and not in 
Runx1+/+ mice, the most frequent was at Evi1 locus, seen in 5 Runx1-/- mice out of 63. 
Evi1 also has an established role in promoting stemness and it regulates stem cell 
proliferation through GATA2 expression (Yuasa et al., 2005). Since Runx1-/- stem cells 
undergo exhaustion, they would require genetic alterations in a gene involved in stem cell 
maintenance for leukemia development. Coincidentally, the most frequent integrations in 
Runx1-/- leukemia cases were near known stem cell genes such as Gfi1 and Evi1 and cell 
cycle regulator Evi5 which may play a role in stemness. These integrations could result in 
overexpression of these genes which may cooperate with Runx1-/- status in initiation 
and/or progression to leukemia. Hence, I decided to carry out further studies of 
cooperation between Runx1-/- status and overexpression of Gfi1, Evi5 and Evi1 in the 






















Figure 4.1: Viral integrations at Gfi1/Evi5 locus frequently seen in Runx1-/- mice 
Schematic diagram of retroviral integration sites in Runx1+/+ (blue) and Runx1-/- 
(purple) leukemias. Numbers are unique to each leukemic mouse. Thin bent arrows 
represent the retrovirus integration and its direction of integration. The two genes Gfi1 
(grey) and Evi5 (green) span from their start sites (ATG) to stop sites (TGA) with shaded 
boxes representing exons. * Leukemia cases in which expression of Gfi1 and Evi5 was 












































Figure 4.2: Integrations at Gfi1/Evi5 locus result in overexpression of Evi5 
QRT-PCR analysis of Gfi1 and Evi5 expression in PB of leukemic samples harboring 
integrations at Gfi1/Evi5 locus (*), integrations within the Evi5 gene (‡) and 3 control 
samples with no integrations at this locus. Data are represented as fold change relative to 







Table 3: Cooperating genetic changes in leukemic mice in group 1 and 2 
Classification of genes near CIS (black) and RIS (violet) identified in this study that 
correspond to known CIS from RTCGD database; and genes near RIS from this study 
(blue) which may have a role in oncogenesis, based on their ** known or predicted 
function. Underlined genes have retroviral integration inside the gene. * Unclassified 
leukemia cases which could belong to group 1 or 2; they showed early onset of disease, 
no enlargement of thymus/lymph node, and no FACS data. ‡ RIS information is not 







ID Genotype Stem cell ** Proliferation** 
Tumor 
supressor** Novel 
       
Group 1 #696 Runx1-/- Evi5 cMyc   
Myeloid #708 Runx1-/- Evi1 Pik3cd  Mapk9 (Jnk) Slis6 
Leukemia #714 Runx1-/- Evi5 Cyclin D3, Cyclin D2 Dab2  
 #807 Runx1-/-  Ncoa2  Ing4  
 #966 Runx1-/- Evi1 Il6st   
       
Group 2 #641 Runx1-/-  Cyclin D3, Cyclin D2 Sh3md2, Stag1 Slis7 
Myeloid+T-cell #770 Runx1-/-  Cyclin D3, Sema4d Gadd45 Slis6 
Leukemia #775 Runx1-/-  cMyc   
 #779 Runx1-/-  cMyc Nkd1 Slis7 
 #813 Runx1-/- Evi5    SlisX 
 #819 Runx1-/- Evi5    
 #821  Runx1-/-     
 #948 Runx1-/- Evi5 Nmyc    
 #969 Runx1-/- Evi5, Evi1 Nmyc, Cyclin D1 Mad1l1  
 #972 Runx1-/-     
 #974 Runx1-/- Lmo2 cMyc, Cyclin D3, Lef1   
 #982 Runx1-/- Evi5  Stag1 SlisX 
 #691‡ Runx1-/-     
 #663 Runx1+/+ Evi5 Pip5k2a   
 #690 Runx1+/+ Lmo2  Foxp1  
 #693 Runx1+/+  Tnfrsf191 Tspan32  
       
Unclassified * #2 Runx1-/- Evi5 Nmyc, Sept9, Pim2   
 #4 Runx1-/- Evi5, Hes1 Il2  SlisX 
 #838 Runx1-/- Evi5     
  #998 Runx1-/- Evi5       
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However, other genes identified in the retroviral mutagenesis screen could also 
cooperate with Runx1-/- status in leukemogenesis through alternate ways. Integrations 
near c-Myc, Cyclin D2 and Cyclin D3 genes were also more frequent in Runx1-/- mice. c-
Myc is a well known protooncogene that causes uncontrolled proliferation of cells when 
overexpressed. Cyclin D2 and D3 are G1 cyclins and dysregulation of their expression 
could lead to abnormal cycling of cells. In most leukemic cases, overlapping CIS as well 
as RIS near genes which may play a role in leukemogenesis were found which may 
represent second and third hits in multi-step leukemogenesis. A comprehensive list of 
interesting genes near CIS or RIS in group 1 and 2 leukemia cases is given in Table 3. 
 
Overexpression of EVI5 cooperates with Runx1-/- status in long term maintenance 
of aberrant stem/progenitor cells in vitro 
The CIS genes chosen for studies of cooperation with Runx1-/- status were Gfi1, Evi5, 
and Evi1, due to high frequency of viral integrations near these genes in Runx1-/- 
leukemias. Moreover, they were suspected to prevent exhaustion of Runx1-/- stem cells 
due to their known function in stemness and thus contribute to Runx leukemogenesis. In 
order to study the cooperation between Runx1-/- status and overexpression of these genes, 
in the maintenance of aberrant Runx1-/- stem cells, I employed in vitro assays using BM 
from Runx1-/- and control Runx1+/+ littermates transfected with retroviral MIG vector 
carrying EVI5, GFI1 or EVI1. To assess the effect of overexpression of these candidate 
oncogenes in immature hematopoietic cells, the cKit+ fraction of transfected cells was 
isolated by FACS and subjected to the experiments.  
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 Serial replating colony assay was first carried out to assess the ability of cKit+ 
immature cells to form colonies in successive rounds of replating, referred to as round 1 
and round 2. In round 1 of colony assay, mock vector transfected Runx1-/- cells showed 
significantly higher colonies than Runx1+/+ cells. However, after replating, in round 2, 
these cells showed very few colony numbers (Figure 5.1). On the other hand, Runx1-/- 
cells transfected with EVI5 and EVI1 showed fewer numbers of colonies than mock 
transfected cells in round 1 of colony assay, but they formed a higher number of colonies 
after replating, in round 2, than mock transfectants. On Runx1+/+ background, EVI5, 
EVI1 and mock transfectants formed similar number of colonies in round 1; and in round 
2, they formed significantly lower number of colonies. GFI1 ovexpression resulted in no 
colonies on Runx1+/+ background and very few colonies on Runx1-/- background right 
from first round of colony assay. In round 2, colony numbers were still very few. In terms 
of synergy between transfected genes and Runx1-/- status in maintenance of 
stem/progenitor cells, EVI5 showed highest synergy because EVI5 transfected Runx1-/- 
cells formed highest number of colonies in round 2. EVI1 overexpression showed a mild 
synergy (Figure 5.1). These results indicate that Runx1-/- cells proliferate abnormally as 
shown by the higher capability of colony formation of these cells in round 1. 
Overexpression of genes such as EVI5 helps to prevent this abnormal proliferation and 






















































Figure 5.1: EVI5 overexpression shows highest synergy with Runx1-/- status in 
serial replating colony assay 
Colony assay of Runx1+/+ and Runx1-/- BM cells transfected with mock vector, EVI5, 
GFI1 and EVI1. Transfected (GFP+), immature (c-Kit+) cells were used for round 1 of 
colony assay and cells harvested from colonies after 10 days were used for round 2. 





LTC-IC assay was performed to further confirm the synergy between 
overexpression of EVI5 and Runx1-/- status in stem cell maintenance. The number of 
colony forming cells scored after more than 30 days culture of transfected Runx1-/- and 
Runx1+/+ stem/progenitor cells (GFP+ c-Kit+) on OP9 stromal cells, which support the 
maintenance of HSC in vitro, is considered to reflect the self-renewal capacity of stem 
cells. The plating efficiency (colony number) of Runx1-/- cells with overexpression of 
EVI5 gene was much higher than that of mock transfected Runx1-/- cells or EVI5 
transfected Runx1+/+ cells, suggesting that Runx1-/- cells overexpressing EVI5 maintain 
a higher number of stem cells (Figure 5.2A and B). Replating of cells after 30 days of 
 78
culture on new OP9 stromal cells and counting cobblestone area-forming cells (CAFC) 3 
to 4 days later further strengthened this observation because Runx1-/- cells carrying EVI5 
showed a high number of CAFC, significantly higher than Runx1-/- cells transfected with 
mock vector or EVI5 overexpressing Runx1+/+ cells (Figure 5.2C). Furthermore, colony 
assay and CAFC assay after 30 more days of culture of replated cells (total 60 days after 
initial transfection) still showed a high number of colonies and CAFC in Runx1-/- cells 
overexpressing EVI5 as compared to other combinations. GFI1 and EVI1 transfected 
Runx1+/+ or Runx1-/- cells did not show any colony or CAFC after 30 days of LTC 
(Figure 5.2A and C). 
Morphological analyses of cells after 30 and 60 days of LTC revealed the 
presence of a large number of immature cells with characteristically large nucleus and 
basophilic cytoplasm in Runx1-/- cells overexpressing EVI5. Runx1-/- cells transfected 
with mock vector and Runx1+/+ cells overexpressing EVI5 showed completely 
differentiated mast cell morphology after both 30 days and 60 days of LTC (Figure 
5.2D). 
Taken together, it is clear that the overexpression of EVI5 strongly cooperates 
with Runx1-/- status in maintenance and proliferation of stem cells in vitro, rather than 
overexpression of GFI1 or EVI5. Furthermore, Runx1-/- status and EVI5 alteration have 
to coexist for robust stem cell maintenance and either of these alterations alone cannot 
sustain the continued maintenance of stem cells. Hence, it is interesting to further verify 
if these 2 genetic alterations can also cooperate in vivo and maintain Runx1-/- stem cells 
without exhaustion and whether EVI5 overexpression can rescue the progressively 






















Figure 5.2: EVI5 overexpression and Runx1-/- status synergize in long term 
maintenance of stem cells 
Graphical representation of (A) colony assay and (B) CAFC assay of immature cells from 
Runx1+/+ and Runx1-/- BM transfected with mock MIG vector, EVI5, GFI1 and EVI1, 
after 30 and 60 days of long term culture. Pictures of (C) Colonies and (D) Morphology 
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Overexpression of EVI5 prevents exhaustion of Runx1-/- stem cells in vivo 
In order to assess the in vivo effect of overexpressing EVI5 in Runx1-/- cells, I 
transplanted Runx1+/+ and Runx1-/- BM cells transfected with EVI5 gene into 
sublethally irradiated (6 Gy) recipient mice. The percentage of GFP positive cells in PB 
was checked at regular intervals after transplantation to assess the reconstitution ability of 
Runx1+/+ and Runx1-/- stem cells overexpressing EVI5. Recipients of Runx1+/+ cells 
overexpressing EVI5 showed stable GFP chimerism throughout, from 6 weeks to 30 
weeks after transplantation, at an average of 20 to 25% (Figure 6.1). This is similar to 
previously described GFP chimerism of recipients of mock transfected Runx1+/+ cells.  
However, the GFP chimerism of mice transplanted with Runx1-/- cells overexpressing 
EVI5 increased progressively, with a mean value of 25% at 6 weeks and 50% at 30 weeks 
(Figure 6.1). This is in contrast to the results seen after transplantation of mock vector 
transfected Runx-/- and Runx1 +/+ cells described earlier where the contribution of 
Runx1-/- cells to PB of recipient mice decreased progressively (Figure 2.1), probably due 
to stem cell exhaustion. Thus, EVI5 seems to cooperate with Runx1-/- status in vivo also 
by preventing stem cell exhaustion and maintaining an expanded population of aberrant 
Runx1-/- stem cells.  
Serial transplantation experiments were also repeated to check if EVI5 
overexpression in Runx1-/- cells could rescue the defects in long term repopulating 
abilities of Runx1-/- stem cells. Similar to previous experimental setting, both Runx1+/+ 
and Runx1-/- BM cells were transfected with retrovirus carrying EVI5 gene; GFP 
chimerism was monitored for average of 4 months in these recipients following which 
BM cells were transplanted into four sublethally irradiated secondary recipients. Contrary 
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to the previous results where majority of the recipients of Runx1-/- cells died within three 
months of secondary transplantation (Figure 2.3), all the recipients of Runx1-/- cells 
overexpressing EVI5 are alive to date, indicating that these stem cells are still capable of 
reconstituting hematopoiesis in recipients (Figure 6.2). Altogether, it can be concluded 
that EVI5 overexpression can prevent Runx1-/- stem cell exhaustion and render them 
capable of reconstituting hematopoiesis in secondary recipients, thus ensuring the 
survival of the mice.  
Evi5 overexpression and Runx1-/- status cooperate in vivo also to maintain 
aberrant Runx1-/- stem cells which are capable of long term repopulating abilities. In fact, 
the increasing chimerism in PB of recipients transplanted with these cells shows that 
EVI5 overexpression can not only rescue Runx1-/- stem cell exhaustion, but it can also 
maintain an expanded pool of target Runx1-/- stem cells which has a higher probability of 
acquiring further mutations that could make them completely leukemogenic. These 
results validate the high frequency of retroviral integrations, seen near the Evi5 gene in 



























































































































Figure 6.1: EVI5 overexpression rescues Runx1-/- stem cell exhaustion in vivo   
GFP chimerism in recipients of Runx1+/+ (n=5) and Runx1-/- (n=4) BM cells transfected 
with EVI5, 6 and 30 weeks after transplantation. Each open circle represents data from an 
individual mouse and closed red circle is the average of a cohort. Stastical difference 















Figure 6.2: EVI5 rescues Runx1-/- stem cell exhaustion in secondary recipients   
Kaplan-Meier survival curves of secondary recipients of Runx1+/+ (blue) and Runx1-/- 
(red) BM cells transfected with mock MIG vector (dashed line) or MIG vector carrying 
EVI5 (solid line), 4 months after primary transplantation. Circles represent end point of 
analysis. 
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Mechanism of cooperation between Runx1-/- status and EVI5 overexpression 
Before addressing the mechanism of cooperation between EVI5 overexpression and 
Runx1-/- status, it is important to understand why Runx1-/- stem cell exhaustion occurs. 
The reason for this could be cell intrinsic factors or stem cell niche related factors. Since 
immature Runx1-/- cells still maintained their hyperproliferative ability 2 years after 
transplantation (Figure 2.2C), intrinsic changes may not be responsible for stem cell 
exhaustion.  Hence, impaired stem cell interaction with the niche could be a reason for 
Runx1-/- stem cell exhaustion as interaction of stem cells with its niche is important for 
maintaining the integrity and self-renewal properties of stem cells.  
I investigated the possibility of impaired interaction of Runx1-/- stem cells with 
the niche and whether it could be rescued by EVI5 overexpression. FACS analysis of a 
panel of niche related factors in cKit+GFP+ cells from transfected Runx1+/+ and Runx1-
/- BM cells revealed that one of the most important molecules for interaction with the 
stem cell niche, CXCR4, was down regulated in Runx1-/- cells (Table 4). CXCR4 
expression is critical for stem cells to respond to the SDF-1α ligand secreted by the stem 
cell niche, thus enabling the stem cells to home to their niche and interact with it, thereby 
maintaining their stem cell properties. Normal level of CXCR4 expression was restored 
after overexpression of EVI5 in Runx1-/- cells. CD49b, which is an α2 integrin required 
for adhesion to the stem cell niche, was also downregulated in Runx1-/- cells and 
expression restored to normal after overexpression of EVI5 in these cells (Table 4).  
The downregulation of CXCR4 in immature Runx1-/- cells was confirmed by 
qRT-PCR (Figure 7.1A). CXCR4 expression was also downregulated in wild type 
immature BM cells transfected with the dominant negative chimera gene RUNX1-ETO, 
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indicating that stem cell exhaustion due to altered niche interaction may also take place in 
human RUNX1 deficient cells (Figure 7.1B). This result also indicates the importance of 
intact Runx1 transcriptional machinery in maintaining normal levels of CXCR4 
expression. Analysis of the promoter region of human CXCR4 gene revealed the presence 
of 2 RUNX binding sites 28 bp and 90 bp upstream of the transcriptional start site. 
Therefore, we checked if CXCR4 gene expression is directly regulated by RUNX1, using 
the luciferase reporter system. A luciferase reporter containing CXCR4 promoter 
fragment 860 bp upstream of the transcription start site was activated more than 20 fold 
in the presence of RUNX1, when introduced into HL60 leukemic cell line. However, the 
DNA binding defective mutant of RUNX1, R174Q, could not transactivate the CXCR4 
promoter (Figure 7.2).  This indicates that RUNX1 regulates transactivation of CXCR4 in 
a DNA binding dependent manner.  
To confirm the defective niche interaction of Runx1-/- HSC due to reduced 
expression of CXCR4 and CD49b, we assessed the homing capacity of Runx1-/- and 
control Runx1+/+ BM cells to the stem cell niche in the BM, using an in vivo homing 
assay. 5 x 106 BM cells from Runx1-/- and Runx1+/+ littermates were stained with a 
fluorescent dye (CFSE) and injected into lethally irradiated (10 Gy) recipient mice. The 
frequency of Runx1-/- and Runx1+/+ cells present in the recipient BM was assessed by 
flow cytometry 16 hours after transplantation. We found that Runx1-/- cells traffic to the 
BM with significantly reduced efficiency relative to Runx1+/+ cells (Figure 7.3). This 
result suggests that Runx1-/- HSC are impaired in their ability to home and attach to the 























































































































Table 4: Runx1-/- cells express lower levels of some niche interacting molecules 
whose expression is restored by overexpression of EVI5. 
Expression of niche interacting molecules on immature (cKit+) Runx1-/- and Runx1+/+ 



















Figure 7.1: CXCR4 expression is reduced under Runx1 deficient conditions 
(A) QRT-PCR analysis of expression of CXCR4 in immature (cKit+) Runx1+/+ and 
Runx1-/- BM cells. (B) Expression of CXCR4 in cKit+GFP+ cells from wild type BM 
cells transfected with mock MIG vector (blue) or RUNX1-ETO (red). One representative 
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Figure 7.2: CXCR4 is a direct transcriptional target of RUNX1 
Schematic diagram of promoter region of human CXCR4, 860 bp upstream of 
transcription start site, containing 2 RUNX binding sites (grey arrowheads); Luciferase 
assay showing transcriptional activity of wild type RUNX1 (WT) or its mutant form 




















Figure 7.3: Runx1-/- BM cells are defective in homing to the stem cell niche 
 Graph showing percentage of CFSE stained Runx1+/+ or Runx1-/- BM cells found in 
the recipient BM (n = 4 and 6 respectively), 16 hours after transplantation. Stastical 
difference using unpaired student-t test is given at the top right corner. 
-860bp +1 -28bp -90bp 
RUNX sites 
p < 0.001 
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Decrease in levels of CXCR4 and CD49b in Runx1-/- stem cells results in 
impaired interaction with the niche as a result of which these cells may lose their stem 
cell properties, resulting in a gradual decrease in stem cell numbers. EVI5 overexpression 
may rescue defects in niche interaction of Runx1-/- HSC and attenuate stem cell 
exhaustion. In addition, there may be cell intrinsic mechanism also that contributes to the 
strong synergy seen between Runx1-/- status and EVI5 overexpression. In order to find 
these cell intrinsic factors, expression of several genes involved in stem cell function and 
apoptosis were checked in immature (c-Kit+) cell fraction of mock or EVI5 transfected 
(GFP+) BM cells from Runx1+/+ and Runx1-/- mice, by qRT-PCR. Among the 
candidate genes tested, Bmi-1, important for self-renewal of normal and cancer stem cells 
(Iwama et al., 2004); p21, essential for stem cell quiescence (Cheng et al., 2000); and the 
anti-apoptotic gene, Bcl2 which is negatively regulated by Runx family (Klampfer et al., 
1996; Abe et al., 2005), were overexpressed in Runx1-/- cells, and the expression of these 
genes was significantly enhanced by overexpression of EVI5 (data not shown). Thus, 
activation of Bmi1, p21 and Bcl-2, together with rescue of interaction of Runx1-/- stem 
cells with the niche by EVI5 overexpression can explain to some extent the mechanism of 
synergy between Runx1-/- status and EVI5 overexpression in long term maintenance and 
expansion of aberrant stem/progenitor cells.  
 
 
EVI5 is overexpressed in 44% of human RUNX leukemia patients examined 
In order to check if EVI5 overexpression synergizes with loss-of-function of RUNX1 in 
human RUNX1 related leukemia patients, I carried out qRT-PCR on cDNA from BM or 




















































M4 patient samples carrying PEBP2β-SMMHC fusion protein. Both these fusion proteins 
are more commonly found RUNX1 alterations. They are dominant negative factors and 
cause loss-of-function of RUNX1. cDNA from BM of couple of patients who had 
undergone complete remission was used as control. Indeed, very significant 
overexpression of EVI5 was seen in 4 out of 9 (44%)  AML M2 patients examined. Even 
though some of the AML M4 patients showed 2 to 3 fold overexpression as compared to 
control samples, the overexpression was not as significant as what was seen in the 4 
AML M2 cases (Figure 8). Therefore, in human RUNX1 related leukemia cases, 
especially in AML M2 carrying RUNX1-ETO, EVI5 overexpression may synergize with 




Figure 8: EVI5 is overexpressed in human RUNX1 related leukemia with t(8;21)  
Real time RT-PCR analysis of EVI5 expression in human RUNX1 related leukemia 
samples, AML M2 with t(8;21) resulting in RUNX1-ETO fusion protein and AML M4 
with inv(16) resulting in PEBP2β-SMMHC fusion protein. Data are represented as fold 
change relative to BM samples undergoing complete remission (CR-BM).   
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Chapter 4 - Discussion 
 
Loss-of-function of RUNX1 has been implicated in approximately 30% of human AML 
as well as in childhood ALL. Despite the prevalence of RUNX1 loss-of-function mutants 
or dominant negative fusion proteins which impair the function of wild type RUNX1, the 
RUNX1 alteration per se does not cause leukemia. Rather, cells with loss-of-function of 
RUNX1 remain preleukemic and only with acquisition of additional hits, they become 
fully leukemic. In recent years, leukemia has been viewed to originate from leukemia 
stem cells (LSC), a small hematopoietic subpopulation with enhanced self-renewal 
capacity. LSC can arise from normal HSC which has undergone genetic mutations that 
gives it a proliferative advantage together with the inherent property of self-renewal. LSC 
could also arise from immature progenitor cells, which are capable of active proliferation, 
when they acquire mutations that revert them back to stem cell like cells which have self-
renewal properties.  
One of the important points in studies of the role of RUNX1 in leukemogenesis is 
to understand how loss-of-function of RUNX1 is involved in the generation and 
progression of a leukemia initiating cell which could give rise to LSC. Loss-of-function 
of RUNX1 by itself may not be able to give rise to a LSC clone, as is obvious from 
experiments that show that mutations in RUNX1 are present in healthy individuals and 
transgenic or knock-in mice carrying dominant negative fusion proteins do not develop 
spontaneous leukemia. Nevertheless, studies done on conditional Runx1 knockout mice 
have revealed that Runx1 excision results in accumulation of immature stem/progenitor 
cells, with numbers that are approximately 2 to 3 fold higher than wild type cells. Also, 
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Runx1 deficiency alters the properties of hematopoietic stem/progenitor cells, probably 
due to increased expression of critical genes such as Bmi1 and HoxB4 which are involved 
in self-renewal of stem cells and Bcl-2 which is an anti-apoptotic factor. Hence, Runx1 
deficient cells have enhanced self-renewal properties and greater resistance to apoptosis 
than wild type cells (Motoda et al., 2007). Together, this may explain how loss-of-
function of Runx1 predisposes cells to leukemia because it supports the accumulation of 
aberrant stem/progenitor cells that have a growth advantage and could potentially become 
LSC. Interestingly, the observation that Runx1 deficiency concomitantly increases the 
expression of Bmi-1 in mice is further supported by the previous report that describes 
higher BMI-1 expression in AML M0 subtype of leukemia in which RUNX1 often 
harbors biallelic loss-of-function mutations (Sawa et al., 2005).  
 The next intriguing question is how does loss-of-function of RUNX1 make cells 
preleukemic without further progression to full blown leukemia. Why is it that the 
aberrant stem/progenitor cell fraction, with RUNX1 deficiency, does not undergo 
extensive proliferation and give rise to leukemia? Based on our experimental results, the 
reason for this seems to be exhaustion of Runx1-/- stem cells. Despite the initial increase 
in stem/progenitor cell fraction in Runx1-/- mice, the immature cell numbers reduce 
progressively and after a certain period of time the stem/progenitor cell numbers in 
Runx1-/- mice are much lower than those in wild type mice. The evidence for this mainly 
comes from analysis of recipients of BMT of Runx1-/- and control Runx1+/+ cells. This 
experimental setting could be more representative of actual physiological setting rather 
than studying Runx1-/- mice themselves, because in actual leukemia cases, before the 
initiating event, most of the cells in the body are normal wild type cells. Then, 
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presumably, one or few cells get a genetic alteration resulting in loss-of-function of 
RUNX1 and these cells turn into possible leukemia initiating cells. This is recapitulated 
by transplantation of Runx1-/- cells into wild type recipients. Runx1 conditional knockout 
mice themselves may not be as ideal to study the development of leukemia since almost 
all the cells in the mouse, including niche for HSC, lack functional Runx1. 
The reconstitution of PB in recipient mice by donor Runx1-/- cells decreases 
progressively whereas reconstitution by Runx1+/+ cells remains constant throughout. 
Furthermore, 2 years after transplantation, absolute number of immature Runx1-/- cells is 
significantly lower than immature Runx1+/+ cells in the recipient BM. Since the 
immature cell population contains the stem/progenitor fraction, we can conclude that 
there is a decrease in number of Runx1-/- stem/progenitor cells over time which may 
result in declining contribution to hematopoiesis. Therefore, the decrease of Runx1-/- 
cells in PB may not be due to differentiation block of Runx1-/- stem/progenitor cells, but 
rather due to a progressive decline in Runx1-/- stem cell numbers or stem cell exhaustion. 
Serial transplantation experiments also further supported the fact that Runx1-/- stem cell 
exhaustion occurs because they are incapable of reconstituting hematopoiesis in 
secondary recipients and more than half of the recipients die due to pancytopenia.  This is 
a true test of donor stem cell maintenance and functionality because only real long term 
HSC can reconstitute hematopoiesis in secondary recipients when transplanted from 
primary recipients, especially after long intervals. Short term stem cells or progenitors are 
not capable of such hematopoietic reconstitution of secondary recipients. Also, at each 
step of BMT, there is a decrease in stem cell numbers. The fact that majority of 
secondary recipients of Runx1-/- cells die within three months of transplantation indicates 
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that Runx1-/- stem cells are not maintained in primary recipients or in other words 
undergo stem cell exhaustion as a result of which when transplanted into sublethally 
irradiated secondary recipients, they cannot reconstitute hematopoiesis and the secondary 
recipients die due to lack of adequate hematopoiesis. The decreased ratio of quiescent 
CD34- LT-HSC and increased ratio of cycling CD34+ ST-HSC and progenitors amongst 
KSL stem cell fraction in Runx1-/- mice may further help to explain the initial increase of 
stem/progenitor cell compartment followed by stem cell exhaustion. 
 The phenomenon of stem cell exhaustion may explain why loss-of-function of 
Runx1 is only preleukemic and not completely leukemogenic. Cells with Runx1 
deficiency may be able to expand abnormally in the beginning, providing a target pool of 
abnormal stem/progenitor cells for subsequent mutations that can maintain the abnormal 
clones and confer further proliferative advantage to cause full blown leukemia. In the 
absence of such cooperative genetic alterations, Runx1-/- stem/progenitor cells may 
slowly undergo exhaustion, without any leukemia development. In order for the 
preleukemic Runx1-/- cells to progress into leukemic cells, probably one of the most 
important cooperation would be with a genetic alteration that prevents exhaustion of 
Runx1-/- stem/progenitor cells and maintains the abnormal clones in the body till they 
accumulate enough genetic alterations for them to turn into LSC clones that can give rise 
to full blown leukemia. 
 I employed RIM to identify such genetic abnormalities that may cooperate with 
loss-of-function of Runx1 in the development of leukemia. Runx1-/- mice injected with 
retrovirus showed shorter latency and higher incidence of leukemia than wild type 
littermates. This result is consistent with the preleukemic effect of Runx1-/- status which 
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results in accelerated leukemia development after acquisition of additional oncogenic hits. 
Since conditional knockout mice lack functional Runx1, they are probably in a more 
susceptible state to develop leukemia due to accumulation of abnormal stem/progenitor 
cells. Even though, in general, Runx1-/- mice developed leukemia earlier than wild type 
littermates, there were variations in the onset time of leukemia as well as the type of 
cancer in both Runx1-/- and wild type mice. The murine cancers induced by MoMuLV 
virus were classified into early and late onset cases with early onset referring to less than 
6 months after birth and late onset to later than that. Further, they were classified into 4 
different groups based on the kind of leukemia or lymphoma seen in the mice as 
described in the results section. MoMuLV virus is strongly lymphotropic and 
predominantly induces the formation of lymphoid leukemia/ lymphoma which is 
underlined by the fact that in my study also almost all wild type mice developed T-cell 
leukemia/lymphoma. On the contrary, majority of the Runx1-/- leukemias fell into groups 
1 and 2 which were entirely comprised of early onset leukemias with myeloid features. 
This indicates a more dominant contribution of Runx1-/- status in the leukemogenesis of 
these cases as loss-of-function of Runx1 is usually myelotropic. Thus, I decided to focus 
on leukemia cases in groups 1 and 2 for two main reasons; firstly, the genes affected by 
retrovirus integration in these leukemias may show a strong cooperation with Runx1-/- 
status which is probably the reason why these mice develop leukemia earlier than other 
mice and secondly, since these gene alterations cooperate with Runx1-/- status in causing 
leukemia with myeloid features, they may be more relevant to human RUNX1 related 
leukemias which are mainly AML (Table 3). In fact, morphological analysis of leukemic 
cells from some Runx1-/- mice in groups 1 and 2 recapitulated the immature myeloid 
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morphology seen in AML M0 (which sometimes harbors biallelic mutation of Runx1) 
and slightly differentiated myeloid morphology seen in other subtypes such as AML M2 
and M4 (which are associated with fusion genes of RUNX1 or its partner PEBP2β, such 
as RUNX1-ETO and PEBP2β-SMMHC respectively).   
 Identification of retroviral insertion sites in mice leukemias by iPCR revealed a 
large number of integration sites in both Runx1-/- and Runx1+/+ mice. I was specifically 
interested in CIS that occur with high frequency in Runx1-/- mice since they would 
obviously be strong candidates for cooperating genetic alterations in Runx 
leukemogenesis. Interestingly, from the IPCR screen, stem cell related and cell cycle 
related genes turned out to be preferentially affected in Runx1-/- mice. This corroborates 
my hypothesis that gene alterations of a stemness related gene is a likely candidate for 
cooperation with Runx1-/- status as it would help to prevent Runx1-/- stem cell 
exhaustion. Many cell cycle proteins also play a role in stemness and stem cell 
maintenance because HSC self-renewal properties are tightly linked to their cell cycle.  
The prime example of such a CIS is the Gfi1/Evi5 locus where integrations were 
seen in 11 Runx1-/- leukemia cases, majority belonging to groups 1 and 2. Integrations at 
this locus were seen only in two Runx1+/+ leukemia cases. This is a strong indication 
that when Runx1-/- status and integrations at Gfi1/Evi5 locus coexist, the mice develop 
aggressive leukemia quite early and these leukemias show myeloid features despite the 
retrovirus being T-lymphotropic. On the other hand, when these alterations do not coexist, 
that is, when Runx1-/- mice have integrations at other loci, the onset time of leukemia as 
well as the leukemic phenotype can vary. This strongly implies cooperation between 
Runx1-/- status and genetic alterations resulting from integrations at Gfi1/Evi5 locus in 
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development of early onset leukemia with myeloid features. Real time PCR analysis of 
expression levels of Gfi1 and Evi5 to identify the one which is more susceptible to viral 
integrations at this locus revealed the preferential and specific overexpression of Evi5 
over Gfi1 in most of the affected leukemic samples, without much change in Gfi1 levels. 
This implies that Evi5 overexpression could be the cooperating genetic alteration in early 
onset Runx1-/- leukemias with myeloid features carrying integrations at Gfi1/Evi5 locus. 
This was surprising because Gfi1 overexpression was expected to play a synergistic role 
with Runx1-/- status by preventing exhaustion of Runx1-/- stem cells since Gfi1 is known 
to be involved in maintaining self-renewal properties of stem cells (Hock et al., 2004). 
On the other hand, Evi5 has not been implicated in stemness and its role in stem cells or 
other hematopoietic compartments is not known. The known role of Evi5 is in cell cycle 
control where it acts by preventing premature entry of cells into mitosis by stabilizing the 
Emi1 protein which inhibits the APC complex till the cells are ready to enter mitosis 
(Eldridge et al., 2006). Nevertheless, further confirmatory assays of synergy were 
performed for both Gfi1 and Evi5 in the Runx1 deficient and control wild type 
background. 
Before discussing the confirmation of synergy in the physiological setting, it is 
interesting to take a look at the other CIS that have been affected with higher frequency 
in Runx1-/- mice compared to control Runx1+/+ mice (Table 2). Along with the 
Gfi1/Evi5 locus, the most frequent integrations in Runx1-/- mice were seen near the c-
Myc oncogene. 4 out of 11 mice with integrations at this locus also fell into groups 1 and 
2. The strongest evidence for co-operation between overexpression of c-Myc gene and 
Runx1-/- status comes from previously published reports. c-Myc is a well established 
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oncogene; and an oncogenic stimulus in a cell results primarily in hyperproliferation, but 
can also induce detrimental effects. For instance, c-Myc and oncogenic Ras have been 
well described to induce apoptosis and premature senescence in primary cells (Braig et al., 
2005). All these effects, oncogene-induced apoptosis, senescence, and differentiation are 
currently well recognized as a vital fail-safe mechanism to restrict the malignant 
transformation, particularly in the initial development of cancer. It has been shown that 
this response of cellular fail-safe mechanism to overexpression of c-Myc is attenuated by 
overexpression of Runx2 in lymphomas (Blyth et al., 2006). This is because ectopic 
expression of Runx2 leads to a preneoplastic state defined by an accumulation of cells 
with an immature phenotype and a low proliferative rate. The overexpression of c-Myc is 
enough to induce proliferation while Runx2 overexpression in turn prevents apoptotic 
responses which may kill the abnormally proliferative malignant clones with c-Myc 
overexpression. Motoda et al. (2007) showed a similar cooperation between Runx1 
insufficiency (which also leads to accumulation of immature cells with block in cellular 
fail-safe machinery such as apoptosis, senescence and differentiation) and overexpression 
of the Ras oncogene that results in overt proliferation of cells, turning them into 
malignant clones. Thus, it is highly possible that the cooperation of Runx1-/- status and c-
Myc overexpression follows a similar mechanism whereby Runx1-/- status provides a 
target population of abnormal cells that can attenuate the fail-safe mechanism when c-
Myc oncogene is overexpressed, resulting in continued survival and expansive 
proliferation of these abnormal clones, resulting in leukemia.  The changes in 
stem/progenitor cells due to Runx1 impairment may contribute to leukemogenesis by 
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preventing the leukemia initiating clone from being eliminated by the fail-safe 
mechanism normally triggered by oncogenic stimuli.  
The third gene that is more frequently hit in Runx1-/- mice is Evi1 gene. This gene 
is also a known stem cell regulator that is frequently upregulated in leukemias. During 
the last few years, there has been a renewed interest in the role of EVI1 in leukemia since 
there seems to be a strong correlation between detection of EVI1 in the BM of patients 
and poor clinical outcome. It has also long been known that the murine Evi1 locus is a 
preferential integration site of ecotropic retroviruses and that the integration leads to 
myeloid tumors in selected strains of susceptible mice (Mucenski et al., 1988). A recent 
report however indicates that while there is still a significant integration preference at this 
site in non-susceptible mice, in these animals the activation of Evi1 does not induce 
leukemia but it rather leads to a nonmalignant clonal expansion in long-term 
hematopoietic progenitors (Kustikova et al., 2005). There have also been reports of Evi1 
being important for proliferation of stem cells and its overexpression leading to 
myelodysplastic syndrome (Yuasa et al., 2005; Buonamici et al., 2004). The fact that 
Evi1 overexpression can maintain stem/progenitor clones over long periods of time 
makes it quite a prime candidate that may prevent exhaustion of Runx1-/- stem cells.  
Considering the genes that are altered by high frequency of viral integrations in Runx1-/- 
leukemias and the known properties and functions of these genes, altogether, there could 
be 2 distinct mechanisms of cooperation between Runx1-/- status and genetic alterations 
identified by RIM (Figure 9). 
As described above, there is a high frequency of stem cell related genes affected 
in Runx1-/- mice and this is consistent with our hypothesis that overexpression of stem 
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cell related genes may rescue exhaustion of Runx1-/- stem cells and maintain them in the 
body till they acquire additional hits and become completely leukemogenic. For example, 
Gfi1/Evi5 locus was predominantly affected in Runx1-/- mice where Gfi1 is a bona fide 
stem cell related gene. Evi1 is another stem cell related gene preferentially affected in 
Runx1-/- cases. Moreover there are other stem cell related genes such as Hes1 and Lmo2 
which have been affected in Runx1-/- mice albeit only once. From an overview of the 
total number of Runx1-/- leukemias and wild type leukemias harboring integrations near 
stem cell related genes, it can be safely deduced that stem cell related genes are much 
more preferentially affected in Runx1-/- mice.  
For further studies of cooperation between identified genes and Runx1-/- status, I 
chose genes near some of the common integration sites, based on frequency of integration 
and their possible function in stemness, namely GFI1, EVI5 and EVI1. Surprisingly, EVI5 
overexpression showed highest synergy with Runx1-/- status in long term maintenance of 
stem cells as compared to GFI1 and EVI1, both of which are well known to function in 
stem cell maintenance. EVI5 showed synergy with Runx1-/- status in short term 
experiments such as colony replating assay as well as in long term maintenance of 
stem/progenitor cells on OP9 stromal cells in LTC-IC assay. In round 1 of colony assay 
of sorted c-Kit+GFP+ cells, mock transfected Runx1-/- cells showed much higher colony 
numbers than Runx1+/+ cells. This is consistent with the increase in stem/progenitor cell 
fraction seen in Runx1-/- mice. However, when round 1 colonies were harvested and 
replated in round 2, both Runx1+/+ and Runx1-/- transfectants showed either no colonies 
or very few colonies, probably due to inability to maintain immature cells. On the other 




































Figure 9: Schematic representation of (A) Runx1-/- stem cell exhaustion; leukemia 
development by cooperation between (B) Runx1-/- status and overexpression of stem cell 
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showed similar colony number as mock transfectants in round 1 and round 2, whereas 
their overexpression in Runx1-/- cells showed lower number of colonies than mock 
transfectants in round 1. This suppression may be a mode of action for stem cell related 
genes which try to prevent excess proliferation that could lead to further differentiation 
and instead try to push the cells towards a more immature status that gives it long term 
survival properties. Indeed, colony assay results from round 2 showed higher number of 
colonies in Runx1-/- cells transfected with EVI1 and EVI5 compared to other 
combinations. This indicates the maintenance of Runx1-/- cells in an immature state by 
EVI1 and EVI5, probably more effectively by EVI5 since its overexpression in Runx1-/- 
cells showed the highest synergy in colony formation after replating, in round 2. 
Overexpression of GFI1 resulted in significant suppression of colony formation of 
Runx1+/+ and Runx1-/- cells in round 1. Although this behavior of GFI1 is consistent 
with earlier reports describing that overexpression of GFI1 results in an initial 
suppression of proliferation, even after replating, colony numbers were very low. This 
leads to the conclusion that even though in the absence of Gfi1, there is a defect in stem 
cell maintenance, as is clear from Gfi1 knockout mice studies; ectopic expression of 
GFI1 cannot maintain immature status of Runx1-/- cells under these conditions.   
The above observations are further strengthened by the results from LTC-IC assay. 
Mock transfected Runx1+/+ and Runx1-/- cKit+GFP+ cells could not be maintained on 
OP9 stromal cultures even for 30 days. These cells showed terminal differentiation after 
30 days of culture on stromal cells. Nevertheless, out of the three genes studied for 
cooperation with Runx1-/- status, EVI5 overexpression showed the strongest synergy in 
long term maintenance of stem cells. Runx1-/- stem/progenitor cells transfected with 
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EVI5 could be maintained on OP9 cells for at least 60 days in culture and these long 
surviving cells retained stem cell properties as evidenced by the presence of high 
numbers of CAFC, colony forming cells and immature morphology. Usually, only long 
term stem cells can be maintained for such long periods of time on stromal cultures while 
short term stem cells or progenitors and other committed cells undergo terminal 
differentiation. This means that EVI5 overexpression strongly synergizes with Runx1-/- 
status in maintaining the long term stem cells. On the other hand, EVI5 transfected wild 
type cells were incapable of maintaining stem cells and also underwent terminal 
differentiation. This shows very specific cooperation between EVI5 overexpression and 
Runx1-/- status. Surprisingly, such specific cooperation was not seen for other genes such 
as EVI1 and GFI1 even though they are known to be involved in stem cell maintenance. 
Taken together, these results suggest that EVI5 overexpression helps to maintain Runx1-/- 
stem cells for long periods of time, probably by preventing stem cell exhaustion. 
In vivo BMT experiments further strengthened this conclusion. In contrast to 
recipients of mock transfected Runx1-/- cells which showed decreasing percentage of 
GFP+ cells in PB progressively, recipients of EVI5 transfected Runx1-/- cells showed 
increasing GFP chimerism. This strongly indicates that indeed, EVI5 overexpression 
rescues Runx1-/- stem cell exhaustion and in fact helps to maintain an expanded, 
increasing pool of these aberrant stem cells.  Recipients of EVI5 overexpressing wild type 
cells showed similar chimerism as mock transfected wild type cells with a slight decrease 
in GFP chimerism over time. This again underlines the specific synergy between EVI5 
overexpression and Runx1 deficiency, whereby both genetic alterations have to coexist to 
effectively maintain stem cells. Serial transplantation assays further confirmed the above 
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results and in contrast to the higher number of secondary recipients of Runx1-/- cells that 
died within one month, all the secondary recipients of EVI5 overexpressing Runx1-/- cells 
survived with a significant percentage of GFP+ cells in their PB. This implies that EVI5 
overexpression helps to maintain Runx1 deficient stem cells in primary recipients over 
long periods of time and they are capable of reconstituting hematopoiesis in secondary 
recipients, leading to enhanced survival. Thus, both in vitro and in vivo experiments give 
clear evidence that EVI5 synergizes with Runx1-/- status strongly and specifically to 
rescue exhaustion of Runx1-/- stem cells and maintain an expanded pool of these aberrant 
cells. 
Retroviral integrations were seen at the Gfi1/Evi5 locus in 2 wild type mice also 
during RIM experiments. However, in the confirmatory assays, there was not any 
significant effect due to overexpression of EVI5 in wild type cells. The reason for this 
discrepancy could be either of the following. In wild type leukemias, Gfi1 expression 
may be altered by retrovirus insertion because under different conditions such as disease 
phenotype or background, different genes are preferentially expressed due to insertions at 
the same site. Another possibility is that in the wild type background, Gfi1 or Evi5 
overexpression may be cooperating with other genetic alterations in the same tumor in 
leukemia progression; which may not be accurately represented in our cooperation 
verification studies where we focus only on the cooperation between the gene 
overexpression and the background genotype.  
The next step is to gain an insight into the mechanism by which EVI5 
overexpression could rescue Runx1-/- stem cell exhaustion. In order to address questions 
about mechanisms of cooperation, it is important to understand why exactly Runx1-/- 
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stem cell exhaustion occurs. Once I have the answer to this question, I can examine how 
EVI5 overexpression rectifies this problem of stem cell exhaustion. Runx1-/- stem cell 
exhaustion could occur due to cell intrinsic factors or factors involved in the interaction 
with the stem cell niche. Based on experimental data, the Runx1-/- immature cells seem 
to maintain their intrinsic properties throughout without much change in functionality. 
Colony assay results of immature Runx1-/- cells, two years after transplantation, show 
similar propensity as Runx1-/- cells from young mice to form higher number of colonies 
than immature Runx1+/+ cells. This indicates that there is not much change in inherent 
or intrinsic properties of Runx1-/- cells and even 2 years after transplantation; they 
maintain their higher proliferation capability. Therefore, compromised interaction with 
the stem cell niche may be a main reason for Runx1-/- stem cell exhaustion. In vivo 
homing assay of Runx1+/+ and Runx1-/- cells confirmed this hypothesis because when 
equal number of labelled BM cells was transplanted into recipient mice, the recipients of 
Runx1-/- cells showed lower percentage of donor cells in the BM 16 hours after 
transplantation, which confirmed impaired homing efficiency of Runx1-/- cells. 
 A number of molecules expressed by HSC and interacting molecules or chemicals 
in the niche are important for homing and niche interactions of HSC. A comprehensive 
list of niche interaction factors were checked in Runx1+/+ and Runx1-/- BM cells 
transfected with mock vector or EVI5. One of the main niche interacting factors that was 
downregulated in immature cKit+Runx1-/- cells was CXCR4. Overexpression of EVI5 in 
Runx1-/- cells restored normal levels of CXCR4. During steady-state homeostasis, 
CXCR4 is expressed by hematopoietic cells and its ligand, the chemokine SDF-1 
(CXCL12) is expressed in the BM niche. In fact, cells expressing high levels of SDF-1 in 
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both the endosteal niche and the sinusoidal niche are reported to be the real niche cells to 
which the HSC attach. Hence, the CXCR4-SDF-1 interaction is very important for stem 
cell homing and niche interaction, and results in stem cells migrating to and taking up 
residence in the niche, thus regulating stem cell survival and self-renewal. Blockage of 
this interaction by G-CSF (that reduces expression levels of SDF-1) or other agents 
results in increased mobilization of stem cells and decreased retention in the niche. 
Another niche interacting factor, CD49b which is an α2 integrin required for adhesion to 
the stem cell niche was also downregulated in Runx1-/- cells and expression restored to 
normal after overexpression of EVI5 in these cells. Even though the other niche 
interacting molecules examined did not show any differences in the samples analyzed, 
defects in these 2 factors, especially CXCR4, may be enough to impair the interaction of 
Runx1-/- stem cells with their niche. Together, Runx1-/- stem cell exhaustion may be due 
to impaired niche interaction of Runx1-/- stem cells. 
Impaired niche interaction may also help to explain why Runx1-/- stem cell 
exhaustion takes place very gradually. Initially, after transplantation, due to high number 
of cells transplanted and expansion of Runx1-/- stem/progenitor cells, there may be 
enough number of Runx1-/- HSC which home to and interact with the niche; and remain 
functional and reconstitute hematopoiesis. However, during homeostasis, these cells often 
leave their original niche and go into circulation. Once that happens, the circulating 
Runx1-/- HSC may be compromised in homing to and interacting appropriately with 
another niche due to impaired expression of CXCR4 and CD49b (Figure 10A and B). 
Alternatively, since the circulating stem cells are made up of a mixture of normal HSC 
with intact Runx1 and aberrant HSC which lack Runx1 and express lower levels of 
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CXCR4 and CD49b, HSC with Runx1 alteration could be outcompeted by normal wild 
type HSC in establishing adequate interaction with the niche (Figure 10C). This may 
lead to defective self-renewal of Runx1-/- stem cells, leading to loss of stem cells. Since 
the number of circulating stem cells is a small fraction of the actual stem cell pool, and 
because a few of the Runx1-/- stem cells may actually be able to reestablish niche 
interaction, decrease in number of stem cells may not be noticeable till sufficient number 
of stem cells have left their niche, entered circulation and lost their stem cell properties 
due to impaired niche interaction. Thus, this mechanism satisfactorily explains the stem 
cell exhaustion of Runx1-/- stem cells, since it happens gradually and progressively, over 
a long interval. Overexpression of EVI5 may rescue this niche interaction by restoring 
higher levels of CXCR4 and CD49b, making sure that the circulating, aberrant Runx1-/- 
stem cells home back and interact with their niche, thus maintaining leukemia initiating 
clones that could give rise to LSC.  
There may also be additional mechanisms which could explain the synergy 
between EVI5 overexpression and Runx1 deficiency. The known function of EVI5 in cell 
cycle control could also contribute to this synergy. Overexpression of EVI5 leads to 
stabilization of Emi1 which in turn may block the APC complex, preventing mitosis of 







































Figure 10: Schematic representation of mechanism by which impaired interaction of 




of EVI5 transfectants progressively. This may explain the slight decrease of GFP 
chimerism seen in recipients of Runx1+/+ cells overexpressing EVI5. Applying the same 
scenario to Runx1-/- cells overexpressing EVI5, these cells should undergo mitotic arrest 
due to overexpression of EVI5. However, these aberrant cells may not die despite 
prolonged mitotic arrest due to overexpression of anti-apoptotic genes. Consistent with 
this idea, expression studies of mock and EVI5 transfected Runx1+/+ and Runx1-/- cells 
showed that genes involved in self-renewal such as Bmi1, and anti-apoptotic genes such  
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as Bcl-2 were upregulated in Runx1-/- cells and their expression was further enhanced by 
overexpression of EVI5. Thus, EVI5 overexpression may maintain Runx1-/- cells in an 
immature state in part by controlling their proliferation rate, preventing excessive 
proliferation and differentiation and at the same time giving them survival advantage. 
Hence, overexpression of Bcl-2 and Bmi1 could be the cell intrinsic factors that play a 
role in the cooperation between Runx1 deficiency and EVI5 overexpression in 
maintenance of an expanded pool of aberrant stem cells that could give rise to LSC.   
 Seeing the results from mouse studies whereby I identified and confirmed the 
overexpression of EVI5 as a genetic alteration that could cooperate with Runx1 
deficiency in leukemogenesis, I next investigated human RUNX1 related leukemia 
patient samples. Around 40% of the AML M2 patients carrying the RUNX1-ETO fusion 
protein, which inhibits the wild type RUNX1 in a dominant negative fashion, showed 
very significant upregulation of EVI5 expression. This recapitulates the mouse Runx1-/- 
leukemia scenario whereby approximately 40% of the mice which developed leukemia 
with myeloid features had integrations at the Gfi1/Evi5 locus, while the others had 
integrations at other loci, especially near c-Myc. Thus EVI5 overexpression may 
cooperate with loss-of-function of RUNX1 in a significant proportion of human RUNX1 
related leukemia patients. However, there are other key players also that cooperate in 
RUNX leukemogenesis, especially mitogens such as receptor tyrosine kinases including 
c-KIT and oncogenic RAS mutants that have been previously reported and possibly MYC. 
And some of these genetic alterations may even overlap with each other and act as 
second and third hits in RUNX1 related leukemia.  
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In summary, loss-of-function of Runx1 results in a preleukemic state without 
development of full blown leukemia, despite enhanced proliferation of cells after deletion 
of Runx1. This is probably due to stem cell exhaustion of Runx1 deficient cells. Hence, 
for leukemogenesis, subsequent oncogenic hits have to take place before the Runx1 
altered stem cells undergo complete exhaustion. The second hit is most likely to be a 
stem cell related gene that can maintain the aberrant Runx1-/- cells for long periods of 
time till they acquire additional hits which would make them leukemogenic. Since 
exhaustion of Runx1-/- stem cells is a very gradual process, these aberrant cells persist in 
the body for long periods of time and there is adequate time for a second hit to occur 
before complete stem cell exhaustion takes place. This may be a critical point for 
leukemogenesis because rapid proliferation accompanied by exhaustion of aberrant stem 
cells may not confer the required time window for subsequent cooperating alterations and 
the stem cells may undergo complete exhaustion without being able to progress to 
leukemia. For example, deficiency of Pten, which is a well known tumor supressor, leads 
to transient expansion of stem cells. However, Pten deficient mice undergo rapid stem 
cell exhaustion with defects in HSC numbers and repopulating abilities obvious within 
one to three months after conditional deletion of Pten gene (Zhang et al., 2006). This 
rapid exhaustion of Pten deficient stem cells may be the reason why mutations in this 
gene are very rare in human leukemias because the aberrant cells may not have enough 
time to acquire additional cooperating genetic alterations before they are completely 
exhausted and eradicated from the individual despite the initial stem cell expansion. On 
the other hand, Runx1 deficient stem cells, though aberrant, seem to persist in the body 
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long enough to acquire additional genetic alterations which make them leukemic and this 
could explain the high frequency of RUNX1 mutations that are found in human leukemias. 
Evi5 has been identified as a potential second hit whose overexpression could 
cooperate with loss-of-function of Runx1 in leukemia initiation/progression, using mouse 
leukemia model generated by RIM. Overexpression of Evi5 helps to maintain Runx1-/- 
stem cells in vitro and in vivo, thus increasing the chances for development of RUNX1 
related leukemia. This cooperation between Runx1 deficiency and Evi5 overexpression 
appears to be due to restoration of niche interaction properties of Runx1-/- stem cells by 
Evi5 along with overexpression of critical stem cell and anti-apoptotic factors such as 
Bmi1 and Bcl2 respectively. EVI5 overexpression is also seen in significant proportion of 
human RUNX1 related leukemia patient samples carrying RUNX1-ETO fusion gene. 
Thus, EVI5 overexpression seems to be a very strong cooperating genetic alteration with 
loss-of-function of RUNX1 in leukemogenesis. However, the recipient mice transplanted 
with Runx1-/- cells overexpressing EVI5 did not develop leukemia even one year after 
BMT, even though the stem cell exhaustion was definitely rescued. Further genetic 
changes, such as strong mitogenic stimuli, are considered to be required for overt 
leukemia. Indeed, overexpression of oncogenes such as N-Myc, c-Myc or D type cyclins 
that promote cell proliferation were concurrently seen in 5 out of 8 Runx1-/- leukemia 
cases carrying integration outside Evi5 gene in the RIM study (Table 3). In human 
RUNX1 related leukemia, similar mitogenic events such as activating mutations in 
receptor tyrosine kinases including c-KIT and RAS have been previously reported 
(Motoda et al., 2007; Speck and Gilliland, 2002). In fact, out of the 4 human AML M2 
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cases carrying RUNX1-ETO which showed overexpression of EVI5, three cases had 
concurrent activating mutations in c-KIT or FLT3.  
 Understanding the mechanism of RUNX1 related leukemia and elucidation of 
cooperating genetic alterations is for the ultimate purpose of developing specific drugs 
that target only aberrant cells, especially LSC, without affecting normal cells in order to 
achieve complete eradication of leukemic clone. Further studies are required to gain 
deeper mechanistic insights into cooperation between RUNX1 alterations, overexpression 
of EVI5 and other mitogenic stimuli to understand pathways that would provide easy, 
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